finasteride profile

Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	57363
CHEMBL ID	710
CHEBI ID	5062
SCHEMBL ID	5509
MeSH ID	M0027324

Synonym
AB00513901-08
AB00513901-07
BRD-K01095011-001-03-5
(4ar,6as,11ar)-4a,6a-dimethyl-2-oxo-hexadecahydro-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide
4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide(finasteride)
(4ar,6as,7s)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide
4a,6a,9a-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxylic acid (finasteride)
(r)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide
(4ar,4bs,6as,9as,9bs,11ar)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide
bdbm50334788
(4ar,6as,7s,11ar)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide
(17beta-(n-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one
(4ar,4bs,6as,7s,9as,9bs,11ar)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide
(4ar,6as)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide
finasterida
CHEBI:5062 ,
andozac
ym-152
finasteridum
BPBIO1_001027
finasteride, >=98% (hplc), powder
l-652,931
chibro-proscar
propecia
ccris 7438
finasterida [inn-spanish]
brn 4269024
finastid
hsdb 6793
mk-906
n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
finasteridum [inn-latin]
17beta-(n-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one
4-azaandrost-1-ene-17-carboxamide, n-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)-
(5alpha,17beta)-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
n-(2-methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide
(4ar,4bs,6as,7s,9as,9bs,11ar)-n-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxamide
mk-0906
mk 0906
(4ar,4bs,6as,7s,9as,9bs,11ar)-n-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxamide
finpecia
proscar
prostide
NCGC00016965-01
cas-98319-26-7
PRESTWICK3_000717
PRESTWICK2_000717
BSPBIO_000933
MLS001424046
AB00513901
finasteride
smr000466304
MLS000759404
DB01216
cpd000466304
D00321
propecia (tn)
proscar (tn)
98319-26-7
finasteride (jan/usp/inn)
PRESTWICK0_000717
PRESTWICK1_000717
SPBIO_002854
mk 906
propeshia
mk906
MLS001165768
(4ar,4bs,6as,7s,9as,9bs,11ar)-n-tert-butyl-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxamide
HMS2051F09
HMS2090G22
nsc-759318
CHEMBL710 ,
(1s,3as,3bs,5ar,9ar,9bs,11as)-n-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
nsc741485
4-azaandrost-1-ene-17-carboxamide,1-dimethylethyl)-3-oxo-, (5.alpha., 17.beta.)-
finasteride (proscar)
nsc-741485
HMS1570O15
A845840
(1s,3as,3bs,5ar,9ar,9bs,11as)-n-isobutyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;finasteride
HMS2097O15
finasteride [usan:usp:inn:ban]
unii-57gno57u7g
57gno57u7g ,
nsc 759318
nsc 741485
dtxcid50625
dtxsid3020625 ,
NCGC00256334-01
tox21_302744
tox21_201506
NCGC00259057-01
tox21_110717
HMS2235L23
CCG-100937
BCP9000685
BCPP000229
BCP0726000222
finasteride component of entadfi
finasteride [vandf]
finasteride [inn]
finasteride [usp monograph]
finasteride [ep monograph]
finasteride [usan]
finasteride [mart.]
finasteride [who-dd]
finasteride [orange book]
entadfi component finasteride
finasteride [jan]
finasteride [mi]
finasteride [usp impurity]
finasteride [ep impurity]
S1197
AKOS015894916
gtpl6818
HY-13635
CS-1767
(1s,3as,3bs,5ar,9ar,9bs,11as)-n-isobutyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
NC00187
SCHEMBL5509
tox21_110717_1
NCGC00093560-05
KS-1058 ,
DBEPLOCGEIEOCV-WSBQPABSSA-N
(5?,17?)-n-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
finasteride, british pharmacopoeia (bp) reference standard
AB00513901_09
mfcd00869737
(1s,2r,7r,10s,11s,14s,15s)-n-tert-butyl-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide
SR-01000759414-4
sr-01000759414
SR-01000759414-6
finasteride, united states pharmacopeia (usp) reference standard
finasteride, vetranal(tm), analytical standard
finasteride for peak identification, european pharmacopoeia (ep) reference standard
finasteride, european pharmacopoeia (ep) reference standard
HMS3714O15
Q424167
([1-phenyl-meth-(e)-ylidene]-amino)-aceticacidethylester
140375-21-9
BRD-K01095011-001-15-9
EX-A1951
nsc-757443
nsc757443
BF164456
urprosan
finasterida (inn-spanish)
finasteride (usp impurity)
finasteride (ep monograph)
pro-cure
finasteridum (inn-latin)
d11ax10
(5alpha,17beta)-n-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
finasteride (usp monograph)
finasteride (mart.)
g04cb01
finasteride (ep impurity)
(5 alpha, 17 beta)-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
17 beta-(n-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one
finasteride (usan:usp:inn:ban)
1h-indeno[5,4-f]quinoline-7-carboxamide, n-(1,1-dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4ar,4bs,6as,7s,9as,9bs,11ar)-
Z1501475008

Excerpt	Reference	Relevance
" Finasteride was well tolerated and there was no evidence of increased adverse experiences with increased duration of treatment."	( Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Stoner, E, 1994)	0.29
" Impotence was the most frequent reason for stopping treatment with finasteride and was the most commonly reported adverse reaction to the drug."	( The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Edet, E; Freemantle, S; Mann, RD; Pearce, G; Stephens, MD; Wilton, L, 1996)	0.29
" The results of this study strongly suggest that this drug is acceptably safe when used in accordance with the current prescribing information."	( The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Edet, E; Freemantle, S; Mann, RD; Pearce, G; Stephens, MD; Wilton, L, 1996)	0.29
"onset, course and resolution of all adverse events during the treatment period."	( Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Afridi, SK; Boake, RC; Elhilali, MM; Fradet, Y; Nickel, JC; Perreault, JP; Pommerville, PJ, 1996)	0.29
" In the safety analysis, the proportion of patients who experienced any adverse event was similar in the two groups (81."	( Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Afridi, SK; Boake, RC; Elhilali, MM; Fradet, Y; Nickel, JC; Perreault, JP; Pommerville, PJ, 1996)	0.29
" Within each age cohort, no significant differences were found between the placebo and finasteride-treated patients in the incidence of cardiovascular adverse events."	( Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Bruskewitz, R; Cook, TJ; Holtgrewe, HL; Kaplan, SA; Lund, RH; Meehan, A; Mobley, D; Narayan, P; Saltzman, B; Waldstreicher, J; Weiner, S; Wells, G, 2001)	0.31
"To systematically review and evaluate the effectiveness and adverse effects of the alpha-antagonist, terazosin, for treating urinary symptoms associated with benign prostatic obstruction (BPO)."	( Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. Howe, W; MacDonald, R; Wilt, TJ, 2002)	0.31
" Adverse effects were greater than with placebo and included dizziness, asthenia, headache and postural hypotension."	( Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. Howe, W; MacDonald, R; Wilt, TJ, 2002)	0.31
" Adverse effects were generally mild but more frequent than with other alpha-antagonists and associated with a two- to four-fold increase in treatment discontinuation."	( Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. Howe, W; MacDonald, R; Wilt, TJ, 2002)	0.31
" In comparative trials, finasteride demonstrated efficacy similar to that of other antiandrogens, with fewer adverse effects."	( Relative safety and efficacy of finasteride for treatment of hirsutism. Marlowe, KF; Townsend, KA, 2004)	0.32
" Reported adverse effects have been minimal."	( Relative safety and efficacy of finasteride for treatment of hirsutism. Marlowe, KF; Townsend, KA, 2004)	0.32
" Five patients in the finasteride and seven in the placebo group reported medication-related adverse events."	( A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). Downey, J; Nickel, JC; Pontari, MA; Shoskes, DA; Zeitlin, SI, 2004)	0.32
"To evaluate the efficacy and adverse effects of doxazosin for treating lower urinary tract symptoms (LUTS) compatible with benign prostatic obstruction (BPO)."	( Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. Howe, RW; MacDonald, R; Wilt, TJ, 2004)	0.32
" Adverse events reported for combined therapy were similar to those with each monotherapy."	( Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. Howe, RW; MacDonald, R; Wilt, TJ, 2004)	0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" 5ARIs were generally well tolerated, with sexual dysfunction the most frequently reported adverse effect, although in only a small proportion of men (1%-8%)."	( A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Miner, M; Naslund, MJ, 2007)	0.34
"Sexual adverse experiences such as erectile dysfunction (ED), loss of libido, and ejaculation disorders have been consistent side effects of finasteride in a maximum percentage of 15% after 1 year of therapy."	( Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? Bartoletti, R; Cai, T; Gavazzi, A; Giubilei, G; Gontero, P; Lombardi, G; Mondaini, N, 2007)	0.34
"The estimation of side effect was conducted at 6 and 12 months using the male sexual function-4 (MSF-4 item) questionnaire and a self-administered questionnaire."	( Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? Bartoletti, R; Cai, T; Gavazzi, A; Giubilei, G; Gontero, P; Lombardi, G; Mondaini, N, 2007)	0.34
" The burden of this nocebo effect (an adverse side effect that is not a direct result of the specific pharmacological action of the drug) has to be taken into account when managing finasteride sexual side effects."	( Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? Bartoletti, R; Cai, T; Gavazzi, A; Giubilei, G; Gontero, P; Lombardi, G; Mondaini, N, 2007)	0.34
" Outcome measures included patient self-assessment, hair count, investigator clinical assessment, global photographic assessment, and adverse effects at short term (≤12 months) and long term (≥24 months)."	( Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Catalano, HN; Guyatt, G; Manzotti, M; Mella, JM; Perret, MC, 2010)	0.36
" Although the adverse side effects of these agents are thought to be minimal, the magnitude of adverse effects on sexual function, gynecomastia, depression, and quality of life remains ill-defined."	( Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. Guay, AT; Hansen, ML; Hassani, J; Traish, AM; Zitzmann, M, 2011)	0.37
" Prolonged adverse effects on sexual function such as erectile dysfunction and diminished libido are reported by a subset of men, raising the possibility of a causal relationship."	( Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. Guay, AT; Hansen, ML; Hassani, J; Traish, AM; Zitzmann, M, 2011)	0.37
"Finasteride has been associated with reversible adverse sexual side effects in multiple randomized, controlled trials for the treatment of male pattern hair loss (MPHL)."	( Persistent sexual side effects of finasteride for male pattern hair loss. Irwig, MS; Kolukula, S, 2011)	0.37
"Despite their efficacy in the treatment of benign prostatic hyperplasia (BPH) the popularity of inhibitors of 5α-reductase (5ARI) is limited by their association with adverse sexual side effects."	( Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction. Balercia, G; Corona, G; Forti, G; Maggi, M; Mannucci, E; Maseroli, E; Rastrelli, G; Sforza, A, 2012)	0.38
" Prescribers of finasteride and men contemplating its use should be made aware of the potential adverse medication effects."	( Persistent sexual side effects of finasteride: could they be permanent? Irwig, MS, 2012)	0.38
" Safety assessments included International Index of Erectile Function (IIEF) and adverse events."	( A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Chung, DE; Kaplan, SA; Lee, RK; Scofield, S; Te, AE, 2012)	0.38
" MFX may be a safe and effective treatment option."	( Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. Tanglertsampan, C, 2012)	0.38
" Changes in lower urinary tract symptoms secondary to benign prostatic hyperplasia were assessed with the I-PSS, erectile dysfunction improvements were assessed with the IIEF-EF (International Index of Erectile Function-Erectile Function) in sexually active men and safety was assessed by evaluating adverse events."	( Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Casabé, A; Da Pozzo, LF; Henderson, RJ; Henneges, C; Roehrborn, CG; Sorsaburu, S; Viktrup, L; Wong, DG; Zepeda, S, 2014)	0.4
" Tadalafil/finasteride coadministration was well tolerated and most adverse events were mild/moderate."	( Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Casabé, A; Da Pozzo, LF; Henderson, RJ; Henneges, C; Roehrborn, CG; Sorsaburu, S; Viktrup, L; Wong, DG; Zepeda, S, 2014)	0.4
" The number and severity of adverse events were similar among treatment groups."	( A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Barboza Martínez, J; Barnes, A; Chetty, D; Ferron-Brady, G; Gubelin Harcha, W; Katsuoka, K; Kawashima, M; Tsai, TF; Tsuboi, R, 2014)	0.4
"Dutasteride can be used to improve urinary symptoms (IPSS and Q max) and reduce TPV but with awareness of its potential adverse events."	( Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. Choi, JY; Park, T, 2014)	0.4
" In some patients the treatment is associated with adverse side effects that could become persistent after therapy discontinuation, resulting in the so-called post-finasteride syndrome (PFS)."	( A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. Cauci, S; Cecchin, E; De Mattia, E; Mazzon, G; Toffoli, G; Trombetta, C, 2014)	0.4
" Molecular events inducing persistent adverse sexual symptoms are unexplored."	( Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia. Belgrano, E; Cauci, S; Di Loreto, C; La Marra, F; Mazzon, G; Trombetta, C, 2014)	0.4
"Two meta-analyses conclude that finasteride treatment of androgenic alopecia (AGA) is safe but do not assess quality of safety reporting."	( Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. Aslam, I; Belknap, SM; Brannigan, RE; Cashy, J; Kiguradze, T; Micali, G; Nardone, B; Temps, WH; West, DP; Yarnold, PR, 2015)	0.42
"For each trial, we assessed quality of adverse event reporting, extracted the number and type of adverse events in treatment and placebo groups, and assessed duration of safety evaluation and adequacy of blinding."	( Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. Aslam, I; Belknap, SM; Brannigan, RE; Cashy, J; Kiguradze, T; Micali, G; Nardone, B; Temps, WH; West, DP; Yarnold, PR, 2015)	0.42
"Of 34 clinical trials, none had adequate safety reporting, 19 were partially adequate, 12 were inadequate, and 3 reported no adverse events."	( Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. Aslam, I; Belknap, SM; Brannigan, RE; Cashy, J; Kiguradze, T; Micali, G; Nardone, B; Temps, WH; West, DP; Yarnold, PR, 2015)	0.42
"The aim of the study is to present the effects of BPH pharmacological treatment on the occurrence of sexually adverse effects in men: changes in sexual desire, erectile, ejaculatory and the orgasmic function."	( Adverse Effects of Pharmacological Therapy of Benign Prostatic Hyperplasia on Sexual Function in Men. Bogdanović, D; Djenić, N; Ignjatović, I; Stojanović, N, )	0.13
" The main adverse effect on sexual function in men is the deterioration in ejaculation or the absence thereof."	( Adverse Effects of Pharmacological Therapy of Benign Prostatic Hyperplasia on Sexual Function in Men. Bogdanović, D; Djenić, N; Ignjatović, I; Stojanović, N, )	0.13
" Recent preclinical and clinical findings indicate that 5α-R inhibitors evoke not only beneficial, but also adverse effects."	( Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know? Bortolato, M; Garcia-Segura, LM; Melcangi, RC; Traish, AM; Zitzmann, M, 2015)	0.42
"Concern regarding adverse effects of finasteride is increasing."	( An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Cauci, S; Chiriacò, G; Mazzon, G; Trombetta, C, 2016)	0.43
"Treatment-induced sexual dysfunctions (SD) are a recurrent and controversial topic in recent literature on the adverse events related to the use of 5-alpha-reductase inhibitors (5ARIs) (1, 2)."	( Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs. Pirozzi Farina, F; Pischedda, A, 2016)	0.43
" Consequently, any possible clinical/paraclinical elements that might predict these adverse effects would be useful in the selection of a therapeutic strategy for male androgenic alopecia."	( Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia? Baleanu, BC; Georgescu, SR; Motofei, IG; Paunica, S; Rowland, DL; Tampa, M, 2016)	0.43
" The reported adverse effects are notable in some patients, consisting in signs and symptoms that are encountered both during finasteride administration and after treatment cessation."	( Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain. Baconi, D; Balalau, C; Baleanu, BC; Constantin, V; Georgescu, SR; Motofei, IG; Paunica, S; Rowland, DL; Stefanescu, E; Tampa, M, 2016)	0.43
" A review of 20 peer-reviewed articles found that very few side effects, or adverse events, related to sexual function have been reported in studies in which dutasteride or finasteride has been used to treat hair loss in women."	( Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review. Eglini, AN; McMichael, AJ; Seale, LR, 2016)	0.43
" However, little is known about the differences in adverse effects between these two drugs."	( Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Li, Q; Wu, M; Yu, Q, 2016)	0.43
"Finasteride is currently used extensively for male androgenic alopecia and benign prostatic hyperplasia; however, some adverse effects are severe and even persistent after treatment cessation, the so-called 'post-finasteride syndrome'."	( Safety Profile of Finasteride: Distribution of Adverse Effects According to Structural and Informational Dichotomies of the Mind/Brain. Georgescu, SR; Manea, M; Motofei, IG; Păunică, I; Rowland, DL; Sinescu, I, 2017)	0.46
"Finasteride has proved to be relatively safe and effective in the therapeutic management of male androgenic alopecia."	( Post-Finasteride Adverse Effects in Male Androgenic Alopecia: A Case Report of Vitiligo. Balalau, C; Baleanu, BC; Constantin, VD; Georgescu, SR; Manea, M; Motofei, IG; Paunica, S; Rowland, DL; Sinescu, I; Tampa, M, 2017)	0.46
" However, they are associated with some transient and even permanent adverse effects."	( [Finasteride adverse effects: An update]. Álvarez-Véliz, S; Berroeta-Mauriziano, D; Carrasco-Zuber, JE; Carreño-Orellana, N; Moll-Manzur, C; Porras-Kusmanic, N, 2016)	0.43
"Treatment of AGA with 5α-reductase inhibitors lead to variable adverse effects and relatively unstable results (therapeutic efficacy ending with treatment cessation), so the choice of optimal therapy is not straightforward."	( Androgenetic alopecia; drug safety and therapeutic strategies. Baconi, DL; Bălălău, C; Constantin, VD; Georgescu, SR; Motofei, IG; Păunică, I; Păunică, S; Rowland, DL; Sârbu, MI; Tampa, M, 2018)	0.48
" Thus, finasteride preserves important physiological roles of dihydrotestosterone (unrelated to AGA) and, in addition, its adverse effects seem to be (at least in part) predictable."	( Androgenetic alopecia; drug safety and therapeutic strategies. Baconi, DL; Bălălău, C; Constantin, VD; Georgescu, SR; Motofei, IG; Păunică, I; Păunică, S; Rowland, DL; Sârbu, MI; Tampa, M, 2018)	0.48
" However, the concern regarding adverse effects of finasteride use has been rising."	( A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. Chalermroj, N; Khunkhet, S; Srisuwanwattana, P; Suchonwanit, P, 2018)	0.48
" Changes in plasma dihydrotestosterone levels and adverse events were recorded."	( A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. Chalermroj, N; Khunkhet, S; Srisuwanwattana, P; Suchonwanit, P, 2018)	0.48
" There were also no systemic adverse events reported by patients in both groups."	( A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. Chalermroj, N; Khunkhet, S; Srisuwanwattana, P; Suchonwanit, P, 2018)	0.48
" The two drugs appear to show similar rates of adverse reactions, especially in sexual dysfunction."	( The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Cui, Y; Gao, Z; Ma, J; Song, S; Wu, J; Zhou, Z, 2019)	0.51
" On the other hand, 5-ARI monotherapy and in particular Finasteride alone is currently getting focus of attention especially due to lack of systematic reviews investigating efficacy outcomes and/or adverse events associated."	( Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature. Antonelli, A; Busetto, GM; Celia, A; Chung, BI; Cindolo, L; D'Agostino, D; De Berardinis, E; Del Giudice, F; Kim, JH; Maggi, M; Minervini, A; Porreca, A; Rocco, B; Romagnoli, D; Schiavina, R; Sciarra, A, 2020)	0.56
"Aim of the present critical review was to analyze current knowledge of clinical efficacy and incidence of adverse events associated with 5-ARI treatment for LUTS/BPH."	( Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature. Antonelli, A; Busetto, GM; Celia, A; Chung, BI; Cindolo, L; D'Agostino, D; De Berardinis, E; Del Giudice, F; Kim, JH; Maggi, M; Minervini, A; Porreca, A; Rocco, B; Romagnoli, D; Schiavina, R; Sciarra, A, 2020)	0.56
" Parameters of research included prostate specific antigen (PSA), prostate volume (PV), International Prostate Symptom Score (IPPS), postvoid residual urine (PVR), voiding symptoms of IPSS (voiding IPSS), maximum urinary flow rate (Qmax), and adverse events (AEs)."	( Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature. Antonelli, A; Busetto, GM; Celia, A; Chung, BI; Cindolo, L; D'Agostino, D; De Berardinis, E; Del Giudice, F; Kim, JH; Maggi, M; Minervini, A; Porreca, A; Rocco, B; Romagnoli, D; Schiavina, R; Sciarra, A, 2020)	0.56
" There was no significant difference between the combined group and minoxidil- or finasteride-only groups in the number of patients with moderate and mild improvements, hair density change, or adverse events."	( The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. Chen, B; Chen, L; Wang, H; Wang, L; Zhang, J, 2020)	0.56
"To investigate the sexual, physical, and mental adverse effects associated with exposure to 5-alpha reductase inhibitors (5ARIs)."	( An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. Chughtai, B; Harrell, MB; Ho, K; Kaplan, SA; Te, AE, 2021)	0.62
" Reports identified one or more adverse effects, along with all concurrent medications."	( An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. Chughtai, B; Harrell, MB; Ho, K; Kaplan, SA; Te, AE, 2021)	0.62
"BTA is a safe and effective therapeutic strategy for the treatment of AGA without adverse effects, and BTA combined with FNS exhibited a superior therapeutic effect than BTA alone."	( Effectiveness and Safety of Botulinum Toxin Type A in the Treatment of Androgenetic Alopecia. Feng, X; Yu, S; Zhang, M; Zhao, J; Zhao, Z; Zhou, Y, 2020)	0.56
"There is ongoing controversy about the adverse events of finasteride, a drug used in the management of alopecia and benign prostatic hyperplasia (BPH)."	( Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. Basaria, S; Bhojani, N; Cone, EB; Marchese, M; Nguyen, DD; Paciotti, M; Trinh, QD, 2021)	0.62
"To investigate the association of suicidality (ideation, attempt, and completed suicide) and psychological adverse events (depression and anxiety) with finasteride use."	( Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. Basaria, S; Bhojani, N; Cone, EB; Marchese, M; Nguyen, DD; Paciotti, M; Trinh, QD, 2021)	0.62
"This pharmacovigilance case-noncase study used disproportionality analysis (case-noncase design) to detect signals of adverse reaction of interest reported with finasteride in VigiBase, the World Health Organization's global database of individual case safety reports."	( Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. Basaria, S; Bhojani, N; Cone, EB; Marchese, M; Nguyen, DD; Paciotti, M; Trinh, QD, 2021)	0.62
"Suicidality and psychological adverse events."	( Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. Basaria, S; Bhojani, N; Cone, EB; Marchese, M; Nguyen, DD; Paciotti, M; Trinh, QD, 2021)	0.62
"VigiBase contained 356 reports of suicidality and 2926 reports of psychological adverse events (total of 3282 adverse events of interest) in finasteride users (3206 male [98."	( Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. Basaria, S; Bhojani, N; Cone, EB; Marchese, M; Nguyen, DD; Paciotti, M; Trinh, QD, 2021)	0.62
"In this pharmacovigilance case-noncase study, significant RORs of suicidality and psychological adverse events were associated with finasteride use in patients younger than 45 years who used finasteride for alopecia."	( Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. Basaria, S; Bhojani, N; Cone, EB; Marchese, M; Nguyen, DD; Paciotti, M; Trinh, QD, 2021)	0.62
" Incidence and type of adverse events, and cause of discontinuation, did not differ meaningfully between topical finasteride and placebo."	( Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Blume-Peytavi, U; Falqués, M; Galván, J; Jansat, JM; Massana, E; Otero, R; Piraccini, BM; Scarci, F; Tamarit, ML; Tebbs, V, 2022)	0.72
" Adverse effects of the drugs were noted."	( Efficacy, tolerability, and safety of montelukast versus finasteride for the treatment of moderate acne in women: A prospective, randomized, single-blinded, active-controlled trial. Goldust, M; Gupta, A; Mohammadnezhad, F; Rokni, GR; Saeedi, M; Sandhu, S; Shadi, S; Sharma, A, 2021)	0.62
"To highlight treatment options for androgenetic alopecia taking into consideration the efficacy, side effect profiles, practicality of treatment (compliance), and costs to help clinicians offer ethically appropriate treatment regimens to their patients."	( Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. Ablon, G; Fischer, DL; Gade, A; Han, H; Nestor, MS, 2021)	0.62
" Frailty may contribute to both symptom progression and serious adverse events (SAEs), shifting the balance of benefits and harms of drug therapy."	( Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. Bauer, SR; Covinsky, K; Ensrud, KE; Liu, TT; McVary, KT; Newman, JC; Ricke, WA; Suskind, AM; Walter, LC, 2021)	0.62
" Topical finasteride, while not FDA-approved, lacks the systemic adverse effects associated with oral finasteride."	( Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? Gupta, AK; Talukder, M, 2022)	0.72
"To review whether topical finasteride is a safe and effective treatment for male and female pattern hair loss."	( Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? Gupta, AK; Talukder, M, 2022)	0.72
" The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried to identify the ten drugs which were associated the most with the adverse drug reactions (ADRs) recorded as "penile curvature" and/or "Peyronie's disease"."	( Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovi Alnajjar, HM; Boeri, L; Cakir, OO; Capogrosso, P; Castiglione, F; Chiappini, S; Deho', F; Fallara, G; Harvey, H; Montorsi, F; Muneer, A; Rewhorn, M; Salonia, A; Schifano, F; Schifano, N, 2023)	0.91
" The few and widely used monotherapies approved by the US Food and Drug Administration, such as minoxidil or finasteride, are not efficacious in all people and cause adverse events that prevent patient compliance."	( Real-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia. Abidi, Z; Arruda, S; Rapaport, J; Sadgrove, NJ; Sadick, N; Swearingen, A, 2023)	0.91
" esculenta tuber extracts provide potentially safe nutraceutical if applied in the management of benign prostate hyperplasia based on a rat model."	( Safety profile of colocasia esculenta tuber extracts in benign prostate hyperplasia. Agu, PC; Aja, PM; Ajayi, CO; Ifie, JE; Munezero, J; Namale, N; Okoboi, J; Ssedyabane, F; Tusubira, D, 2023)	0.91

Excerpt	Reference	Relevance
" The mean values of the area under the curve (AUC0-24) and Cmax increased linearly in a dose-dependent manner."	( Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volu Morikawa, H; Ohtawa, M; Shimazaki, J, )	0.13
" Multiple-dose coadministration of terazosin and finasteride did not alter the central values of steady-state pharmacokinetic parameters of either drug in a statistically significant manner."	( Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride. Cavanaugh, J; Eason, C; Granneman, GR; Hosmane, B; Locke, C; Samara, EE, 1996)	0.29
" The aim of this study was to assess the potential pharmacokinetic interaction of doxazosin or terazosin when coadministered with finasteride."	( Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin. Chung, M; Hilbert, J; Lawrence, V; Phillips, K; Vashi, V, 1998)	0.3
" Simulations closely predicted the outcome of the repeat dose study, estimated parameters of the pharmacodynamic modelling were generally close to within 88 to 116% of those from the original model and the individual predictions did not indicate any bias."	( Validation of a population pharmacokinetic/pharmacodynamic model for 5 alpha-reductase inhibitors. Hammarlund-Udenaes, M; Hermann, D; Karlsson, MO; Olsson Gisleskog, P, 1999)	0.3
" Therefore, we hypothesize that because of its pharmacokinetic parameters and increased potency against r5AR1, GI198745 is more effective than finasteride in preventing the growth of the rat prostate."	( Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat. Batchelor, KW; Bramson, HN; Hoffman, CR; Kadwell, SH; Kost, TA; Lee, FW; Overton, LK; Simpson Noel, D; Stuart, JD; Tippin, TK; Yeager, RL, 2001)	0.31
" Pharmacokinetic studies of VN/85-1 were conducted in male SCID mice."	( Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. Brodie, AM; Handratta, VD; Jelovac, D; Kataria, R; Long, BJ; Njar, VC; Nnane, IP, 2004)	0.32
" Therefore, we conducted a pharmacokinetic study of oral T in oil, alone or with D or F, in the fasting and fed states in normal men whose endogenous T production was suppressed by the GnRH antagonist acyline."	( Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. Amory, JK; Bremner, WJ; Page, ST, )	0.13
"We sought to assess the possibility of using pharmacokinetic parameters as a predictor of response to benign prostatic hyperplasia (BPH) pharmacotherapy via a randomized, placebo-controlled, animal preclinical trial using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)."	( Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI. Baudendistel, KT; Henry, H; Heverhagen, JT; Jia, G; Knopp, MV; Levine, AL; Polzer, H; Rosol, TJ; von Tengg-Kobligk, H, 2006)	0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" The herbal treatment significantly reduced the peak plasma concentration (C(max)), the area under the plasma concentration-time curve (AUC(0-24h)) and the elimination half-life (t(1/2)) of finasteride."	( The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Bondesson, U; Hedeland, M; Knutson, L; Lennernäs, H; Lundahl, A, 2009)	0.35
" The method was successfully applied to a pharmacokinetic study of finasteride in healthy volunteers following oral administration."	( Rapid determination of finasteride in human plasma by UPLC-MS/MS and its application to clinical pharmacokinetic study. Hwang, SK; Kim, EH; Kim, SD; Lee, HW; Lee, M; Lim, MS; Park, J; Phapale, PB; Yoon, YR, 2010)	0.36
" We developed a pharmacokinetic model incorporating a compartment that represents the binding of finasteride to 5alphaR."	( Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Hori, S; Ohtani, H; Satoh, H; Sawada, Y; Suzuki, R, 2010)	0.36
"Benign prostatic hyperplasia and prostate cancer can be treated with the 5α-reductase inhibitors, finasteride and dutasteride, when pharmacodynamic biomarkers are useful in assessing response."	( Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry. Andrew, R; Faqehi, AM; Homer, NZ; Hughes, KA; Naredo, G; Stewart, LH; Upreti, R; Walker, BR, 2015)	0.42
"The primary aim of this study was to evaluate whether there was clinically significant pharmacokinetic (PK) interaction between finasteride and tamsulosin in healthy Chinese male subjects."	( Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3-period crossover study in healthy Chinese male volunteers. Chen, W; Chu, N; Li, X; Wang, G; Wang, J; Xu, H; Yang, M; Yuan, F, 2015)	0.42
" Pharmacokinetic parameters were estimated via noncompartmental methods."	( Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3-period crossover study in healthy Chinese male volunteers. Chen, W; Chu, N; Li, X; Wang, G; Wang, J; Xu, H; Yang, M; Yuan, F, 2015)	0.42
" Freeze-dried NPs formulation was subsequently loaded into hard gelatin capsules that were examined for in vitro dissolution and pharmacokinetic behavior."	( Preparation of finasteride capsules-loaded drug nanoparticles: formulation, optimization, in vitro, and pharmacokinetic evaluation. Ahmed, TA, 2016)	0.43
" Finally, FSD clinical pharmacokinetic has been investigated on human volunteers."	( Development of optimized self-nanoemulsifying lyophilized tablets (SNELTs) to improve finasteride clinical pharmacokinetic behavior. Ahmed, TA; Aljaeid, BM; El-Say, KM; Hosny, KM, 2018)	0.48
" An optimized drug micro- and nano-particles were developed, characterized, administered to group of rats, and systemic pharmacokinetic and tissue distribution within target and not-target organs were determined using near-infrared (NIR) spectroscopy technique."	( Effect of finasteride particle size reduction on its pharmacokinetic, tissue distribution and cellular permeation. Ahmed, TA; Al-Abd, AM, 2018)	0.48

Excerpt	Reference	Relevance
"5 mg/day, alone or in combination with topical 2% minoxidil, for 20 weeks to determine the effects on scalp hair growth in balding adult male stumptail macaque monkeys."	( Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. Brunden, MN; Buhl, AE; Diani, AR; Johnson, GA; Kubicek, MF; Mulholland, MJ; Schostarez, HJ; Shull, KL, 1992)	0.28
" Small increases in serum T were observed with finasteride alone and in combination with MK-386 (approximately 10% and 19%, respectively)."	( Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men. Chavez, CM; Constanzer, ML; De Lepeleire, I; De Schepper, PJ; Ebel, DL; Gertz, BJ; Justice, SJ; Lasseter, KC; Schwartz, JI; Shamblen, EC; Van Hecken, A; Wang, DZ; Winchell, GA, 1996)	0.29
"The bioabsorbable SR-PLLA stent combined with finasteride therapy provides a promising new alternative in the treatment of acute urinary retention, especially in patients unfit for surgical therapy."	( A pilot study of a bioabsorbable self-reinforced poly L-lactic acid urethral stent combined with finasteride in the treatment of acute urinary retention from benign prostatic enlargement. Isotalo, T; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T, 2000)	0.31
"To evaluate the likelihood of alpha-adrenergic antagonist (alpha-blocker) discontinuation in combination with dutasteride or finasteride among patients aged > or =65 years with enlarged prostate."	( Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men. Davis, EA; Eaddy, MT; Issa, MM; Lin, PJ; Shah, MB, 2008)	0.35
"To evaluate the clinical effectiveness of transurethral seminal vesiculoscopy (TUSV) combined with finasteride in the treatment of recurrent hemospermia."	( [Transurethral seminal vesiculoscopy combined with finasteride for recurrent hematospermia]. Cui, ZQ; Du, J; Gao, EJ; Lu, HK; Wang, YC; Yu, ZY; Zhou, HJ, 2014)	0.4
"Transurethral seminal vesiculoscopy combined with finasteride is safe and effective for the treatment of recurrent hemospermia."	( [Transurethral seminal vesiculoscopy combined with finasteride for recurrent hematospermia]. Cui, ZQ; Du, J; Gao, EJ; Lu, HK; Wang, YC; Yu, ZY; Zhou, HJ, 2014)	0.4
" However, on the basis of an in vitro-in vivo extrapolation, our data strongly suggested that finasteride is unlikely to cause clinically significant drug-drug interactions mediated via inhibition of the hepatic UGT enzymes involved in drug metabolism in vivo."	( In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug-drug interactions. Bae, SH; Bae, SK; Chin, YW; Kim, D; Lee, SJ; Oh, E; Park, JB, 2015)	0.42
"The on-line preconcentration technique of field-enhanced sample stacking and sweeping (FESS-sweeping) are combined with dispersive liquid-liquid microextraction (DLLME) to monitor the concentrations of finasteride, which is used in the treatment of androgenetic alopecia, and its metabolite, finasteride carboxylic acid (M3), in urine samples."	( Determination of finasteride and its metabolite in urine by dispersive liquid-liquid microextraction combined with field-enhanced sample stacking and sweeping. Chao, YY; Chen, CH; Chen, YL; Lin, YH, 2018)	0.48
"The goal was to explore the efficacy and side effects of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male patients with early stage of androgenetic alopecia (AGA)."	( Clinical observation of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male androgenetic alopecia. Liu, C; Wu, W; Zhang, Y; Zhao, H, 2022)	0.72

Excerpt	Reference	Relevance
" Finasteride is well absorbed after oral administration; peak plasma concentration is reached in as little as one hour."	( Finasteride: a 5 alpha-reductase inhibitor. Steiner, JF, 1993)	0.29
" It is well absorbed after oral administration, with absolute bioavailability in humans of 63% (range 34-108%)."	( Finasteride: the first 5 alpha-reductase inhibitor. Koronkowski, MJ; Sudduth, SL, )	0.13
" Finasteride is well absorbed after oral administration and, while the rate of absorption may be slowed postprandially, the presence of food has no effect on the total bioavailability."	( Clinical pharmacokinetics and pharmacodynamics of finasteride. Steiner, JF, 1996)	0.29
" Dogs showed rapid absorption after oral administration of the low dose, with Cmax reached in the 1-2 hr, bioavailability was estimated to be > 90%."	( Disposition and metabolism of finasteride in dogs. Arison, BH; Carlin, JR; Chiu, SH; Christofalo, P; Ellsworth, RE; Miller, RR; Rosegay, A; VandenHeuvel, WJ, 1997)	0.3
" Neurosteroid replacement is a potential approach to therapy, but natural neurosteroids have poor bioavailability and may be converted to metabolites with undesired progestational activity."	( Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. Reddy, DS; Rogawski, MA, 2000)	0.31
"Two different finasteride (CAS 98319-26-7) tablet formulations were evaluated for their relative bioavailability (Flaxin tablets 5 mg, as the test formulation vs reference formulation, tablets 5 mg) in 23 healthy male volunteers who received a single 5 mg oral dose of each preparation."	( Bioequivalence study of finasteride. Determination in human plasma by high-pressure liquid chromatography coupled to tandem mass spectrometry. de Menezes, FG; de Moraes, ME; de Moraes, MO; De Nucci, G; Ifa, DR; Ribeiro, W, 2001)	0.31
"As local steroid metabolism controls the bioavailability of active steroidal hormones in the prostate, the aim of this study, was to investigate the effects of absence of 5-alpha reductase (5alpha-r) and aromatase (Aro) enzymes on prostatic cellular and extracellular components after long-term inhibition."	( Long-term inhibition of 5-alpha reductase and aromatase changes the cellular and extracellular compartments in gerbil ventral prostate at different postnatal ages. Campos, SG; Corradi, LS; Góes, RM; Santos, FC; Taboga, SR; Vilamaior, PS, 2009)	0.35
"The aims of this study were to compare the bioavailability of finasteride ODTs and standard tablets in healthy adult male Han Chinese volunteers and to determine whether any observed differences exceeded Chinese regulatory guidelines for bioequivalence."	( Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study. Chen, L; Hu, L; Huang, L; Jiang, X; Lan, K; Li, X; Ren, J; Wang, H; Zou, Q, 2009)	0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" Flavonoids such as silibinin, green tea polyphenols, genistein, curcumin have shown great promise, but avenues to improve their bioavailability are requisite."	( Advances in prostate cancer chemoprevention: a translational perspective. Nambiar, D; Singh, RP, 2013)	0.39
"35% relative bioavailability compared with a commercial tablet."	( Self-microemulsifying systems of Finasteride with enhanced oral bioavailability: multivariate statistical evaluation, characterization, spray-drying and in vivo studies in human volunteers. ElShafeey, AH; Fagir, W; Hathout, RM; Sammour, OA, 2015)	0.42
" Pharmacokinetic parameters displayed a higher absorption rate and higher area under the curve of the FIN/DM-β-CyD inclusion complex when compared with the drug alone, which indicates an improvement in the absorption and bioavailability of FIN in the DM-β-CyD inclusion system."	( Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins. Farghaly Aly, U; Mady, FM, 2017)	0.46
"Enhance FSD bioavailability in male pattern baldness and benign prostatic hyperplasia."	( Development of optimized self-nanoemulsifying lyophilized tablets (SNELTs) to improve finasteride clinical pharmacokinetic behavior. Ahmed, TA; Aljaeid, BM; El-Say, KM; Hosny, KM, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" Dose-response studies were performed on male rats treated in utero during the period of sexual differentiation with either the potent 5 alpha-reductase inhibitor finasteride or the antiandrogen flutamide."	( Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies. Imperato-McGinley, J; Sanchez, RS; Spencer, JR; Vaughan, ED; Yee, B, 1992)	0.28
"The pharmacology and pharmacokinetics of finasteride are reviewed, and finasteride's clinical efficacy, adverse effects, and dosage in patients with benign prostatic hyperplasia (BPH) are described."	( Finasteride: a 5 alpha-reductase inhibitor. Steiner, JF, 1993)	0.29
"5-100 mg/day regress prostate enlargement; the recommended dosage is 5 mg once/day."	( Finasteride: the first 5 alpha-reductase inhibitor. Koronkowski, MJ; Sudduth, SL, )	0.13
" First, while administration of testosterone to eggs incubating at all male-producing and male-biased intermediate temperatures produced females in a dose- and temperature-dependent manner, significant numbers of intersex individuals resulted from high dosage testosterone treatment to eggs incubating at a female-biased intermediate temperature."	( Role of reductase and aromatase in sex determination in the red-eared slider (Trachemys scripta), a turtle with temperature-dependent sex determination. Bergeron, JM; Crews, D, 1994)	0.29
" Values of t1/2z are higher in elderly men, but no dosage adjustments are necessary."	( Clinical pharmacokinetics and pharmacodynamics of finasteride. Steiner, JF, 1996)	0.29
" After either dosing route, 45% of the plasma radioactivity (as represented by AUC) was parent drug, 43% was metabolite I, and 1% was metabolite IV."	( Disposition and metabolism of finasteride in dogs. Arison, BH; Carlin, JR; Chiu, SH; Christofalo, P; Ellsworth, RE; Miller, RR; Rosegay, A; VandenHeuvel, WJ, 1997)	0.3
" Concentrations of DHT and T before and 7 days after treatment did not differ by dosage of finasteride administered."	( Effect of finasteride on serum concentrations of dihydrotestosterone and testosterone in three clinically normal sexually intact adult male dogs. Castner, S; Hardy, SK; Johnston, SD; Kamolpatana, K, 1998)	0.3
" Thus the model derived from single dose data from healthy volunteers was considered to be valid for the prediction of DHT levels in the patient population after repeated dosing of dutasteride and finasteride."	( Validation of a population pharmacokinetic/pharmacodynamic model for 5 alpha-reductase inhibitors. Hammarlund-Udenaes, M; Hermann, D; Karlsson, MO; Olsson Gisleskog, P, 1999)	0.3
" In two similar experiments, weanling female rats were dosed for 20 days by gavage with vehicle (0."	( Evaluation of the EDSTAC female pubertal assay in CD rats using 17beta-estradiol, steroid biosynthesis inhibitors, and a thyroid inhibitor. Carney, EW; Crissman, JW; Marty, MS, 1999)	0.3
" Dosing extended over postnatal days (pnd) 22-35, 36-50, 36-55 and 22-35, with recovery to pnd 55 or 22-55."	( The peripubertal male rat assay as an alternative to the Hershberger castrated male rat assay for the detection of anti-androgens, oestrogens and metabolic modulators. Ashby, J; Lefevre, PA, )	0.13
" Recently, this assay was evaluated by several laboratories using a variety of dosing schemes."	( Evaluation of the male pubertal onset assay to detect testosterone and steroid biosynthesis inhibitors in CD rats. Carney, EW; Crissman, JW; Marty, MS, 2001)	0.31
" The recommended dosage is 5 mg a day, however case reports have show effectiveness with lower doses."	( The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia. Geller, J; Sullivan, MJ, 2002)	0.31
" No dosage titration is needed for ER alfuzosin, and its onset of peak action is within days of the start of treatment."	( Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Lee, M, 2003)	0.32
" Castration of sexually immature Sprague-Dawley rats was performed between post-natal days 42 and 46 whilst dosing of the chemical over 10 days was performed between post-natal days 53 and 67."	( Evaluation of the rodent Hershberger assay using three reference endocrine disrupters (androgen and antiandrogens). Bars, RG; Kennel, PF; Pallen, CT, )	0.13
" The objective of this study was to identify the optimal dosage of finasteride and to evaluate its efficacy and safety in the treatment of Japanese men with male pattern hair loss."	( Finasteride in the treatment of Japanese men with male pattern hair loss. Harada, S; Hayashi, N; Igarashi, A; Kawashima, M; Kitahara, H; Maeguchi, M; Matsuda, T; Mizuno, A; Murata, Y; Natsumeda, Y; Nogita, T; Takahashi, K; Toda, K; Tsuboi, R; Ueki, R; Yamada, M; Yamazaki, M, )	0.13
" Although the standard preparation is suitable for once-daily dosing in BPH, it has to be titrated through three steps to its final dose."	( After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Doggrell, SA, 2004)	0.32
" Higher rates of twice-daily (or 2 units per day) dosing are associated with higher incremental cost-effectiveness ratios."	( Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. Chrischilles, EA; Klein, RW; Kreder, KJ; Ohsfeldt, RL, )	0.13
" However, at their effective dosage regimes, VN/85-1 and VN/87-1 were each as effective as castration and more effective than finasteride or casodex, an anti-androgen used for prostate cancer (PC) therapy."	( Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. Brodie, AM; Handratta, VD; Jelovac, D; Kataria, R; Long, BJ; Njar, VC; Nnane, IP, 2004)	0.32
" The main reasons of a poor internal validity in 3 studies were the short follow-up, the missing percentage, the absence of a placebo group and a dosage bias."	( [Analysis of the scientific evidence of the combination therapy in benign prostatic hyperplasia]. Millán Rodríguez, F, 2005)	0.33
" It is unclear whether the success was due to a higher dosage of finasteride (2."	( Finasteride treatment of female pattern hair loss. Iorizzo, M; Piraccini, BM; Tosti, A; Vincenzi, C; Voudouris, S, 2006)	0.33
"05) inhibits growth of LNCaP human prostate cancer xenografts in intact male nude mice, but this inhibition is not as great as that by equimolar oral dosing with dutasteride."	( Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Becker, RE; Dalrymple, SL; Denmeade, SR; Isaacs, JT; Xu, Y, 2006)	0.33
" Thereafter, a dose-response effect of different doses of benzylglucosinolates (0."	( Effect of two different extracts of red maca in male rats with testosterone-induced prostatic hyperplasia. Gasco, M; Gonzales, GF; Maldonado, C; Mormontoy, J; Pajuelo, M; Portella, J; Rodriguez, D; Vasquez, V; Villegas, L, 2007)	0.34
" There was no suggestion of a dose-response relationship between exposure to 5-alpha reductase inhibitors when the exposure was stratified into tertiles of total exposure (P = ."	( Association between 5-alpha reductase inhibition and risk of hip fracture. Cheetham, TC; Haque, R; Jacobsen, SJ; Loo, RK; Shi, JM, 2008)	0.35
"Especially in obese men and in those > 70 years old, SHBG dosage is important to calculate FT levels and diagnose hypogonadism."	( Laboratory diagnosis of late-onset male hypogonadism andropause. Buksman, S; Carmo, AM; Clapauch, R; Marinheiro, L; Pessoa, I, 2008)	0.35
" On the seventh day of each dosing period, serum testosterone, DHT and oestradiol were measured at baseline and 1, 2, 4, 8, 12, 13, 14, 16, 20 and 24 h after the morning dose."	( Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride. Amory, JK; Christenson, P; Dudley, RE; Hull, L; Leung, A; Roth, MY; Swerdloff, R; Wang, C, 2011)	0.37
"Reversed-phase high-performance liquid chromatography (RP-HPLC) and thin-layer chromatography (TLC) methods have been developed and validated for simultaneous estimation of tamsulosin hydrochloride and finasteride in bulk drug and in combined dosage forms."	( Validated RP-HPLC and TLC methods for simultaneous estimation of tamsulosin hydrochloride and finasteride in combined dosage forms. Patel, DB; Patel, NJ, 2010)	0.36
" In this study, we investigated a dosing time-dependent effect and safety of FIN in rats."	( Influence of dosing time on the efficacy and safety of finasteride in rats. Ando, H; Fujimura, A; Kumazaki, M; Maekawa, T; Motosugi, Y; Takada, M; Tateishi, M; Ushijima, K, 2011)	0.37
" Dosage analysis showed that lower doses of finasteride were associated with higher overall and prostate cancer risks."	( A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia. Chang, SN; Kao, CH; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2012)	0.38
" experimental T and DHT levels and prostate size are depicted, demonstrating the model accurately described an approximate 77% decrease in prostate size and nearly complete depletion of prostatic DHT following 21 days of daily finasteride dosing in rats."	( A multiscale, mechanism-driven, dynamic model for the effects of 5α-reductase inhibition on prostate maintenance. Barton, HA; Zager, MG, 2012)	0.38
" The specified limits for the USP uniformity of dosage units assay (98."	( Development and validation of an UPLC method for determination of content uniformity in low-dose solid drugs products using the design space approach. Fariña, JB; Llabrés, M; Oliva, A, 2013)	0.39
" For Gleason 2-6 cancers, results were inconsistent across treatment arms with a suggestion of increased risk in the placebo arm only; however, there was no dose-response relationship."	( Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Goodman, PJ; Kristal, AR; Neuhouser, ML; Peters, U; Schenk, JM; Song, X; Tangen, CM; Till, CA; Torkko, KC, 2014)	0.4
" Furthermore, a dosage analysis showed that higher doses of finasteride were associated with higher osteoporosis diagnosis risk (OR = 1·68; 95% CI, 1·01-2·81), relative to the patients not using 5ARIs."	( A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia. Hsieh, YW; Kao, CH; Lin, CL; Lin, WL; Sung, FC; Wu, CH, 2015)	0.42
" Blood samples were collected up to 48 hours after dosing on study day 1 and up to 24 hours after dosing on study day 9 for determination of plasma concentrations with a validated LC-MS/MS method."	( Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3-period crossover study in healthy Chinese male volunteers. Chen, W; Chu, N; Li, X; Wang, G; Wang, J; Xu, H; Yang, M; Yuan, F, 2015)	0.42
" Furthermore, the dosage analysis showed that there were no significant associations between ACS risk and uses of a single drug medication regardless the dosages."	( 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia. Chou, CH; Kao, CH; Lin, CL; Lin, MC; Sung, FC, 2015)	0.42
"025); scores were not significantly different between treatments for satisfaction with dosing or side-effects (both P ≥ 0."	( Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing f Casabé, A; Glina, S; Henneges, C; Roehrborn, CG; Sorsaburu, S; Viktrup, L, 2015)	0.42
"The goal was to develop an optimized transdermal finasteride (FNS) film loaded with drug microplates (MIC), utilizing two-step optimization, to decrease the dosing schedule and inconsistency in gastrointestinal absorption."	( Transdermal film-loaded finasteride microplates to enhance drug skin permeation: Two-step optimization study. Ahmed, TA; El-Say, KM, 2016)	0.43
"Lyophilized tablets could be considered as a good alternative for conventional solid dosage forms especially when loaded with drug nanosystems."	( Development of optimized self-nanoemulsifying lyophilized tablets (SNELTs) to improve finasteride clinical pharmacokinetic behavior. Ahmed, TA; Aljaeid, BM; El-Say, KM; Hosny, KM, 2018)	0.48
"FAERS data suggests that finasteride exposure is reported with a diverse collection of symptoms, particularly in younger men on 1 mg dosage compared to older men on 5 mg."	( A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome. Althof, S; Baas, WR; Butcher, MJ; Clemons, J; Delfino, K; Herberts, M; Holland, B; Kohler, TS; Lwin, A; McVary, KT, 2018)	0.48
" Murine animal models were divided into 8 groups, Sham rats, BPH rats, BPH rats administered with finasteride (1 mg/kg), BPH rats administered with Pule'an (460 mg/kg), BPH rats administered with low, high dosage of QCJ (860 mg/kg, 2580 mg/kg respectively), BPH rats administered with low, high dosage of Fr."	( Chemical profiles of the active fraction from Prinsepia utilis Royle leaves and its anti-benign prostatic hyperplasia evaluation in animal models. Li, X; Peng, C; Peng, Y; Sun, C; Wu, Y, 2021)	0.62
"In our previous study, a long-acting injectable (LAI) formulation of finasteride was prepared as a new dosage form of PROPECIA®, and in vivo pharmacokinetics (PKs)-pharmacodynamics (PDs) was evaluated in beagle dogs."	( Approaches for estimating the clinical starting dose of new dosage forms: An example of a long-acting injectable formulation of finasteride. Cho, HY; Hee Kim, J; Wook Kang, D, 2023)	0.91
" That approach was utilized to estimation of the cited drugs in dosage forms, simultaneously with %recoveries for tadalafil and finasteride of 99."	( Synchronous fluorescence as a green and selective method for the simultaneous determination of finasteride and tadalafil in dosage form and spiked human plasma. Abdelaziz, A; Batekh, AE; Emad, N; Galal, M; Hussien, M; Karem, M; Moukhtar, DA; Salem, H, 2023)	0.91

Role	Description
androgen antagonist	A compound which inhibits or antagonises the biosynthesis or actions of androgens.
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor	An EC 1.3.1.* (oxidoreductase acting on CH-CH group of donor, NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of of 3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+)), EC 1.3.1.22, the enzyme which converts testosterone (CHEBI:17347) into the more potent androgen 5alpha-dihydrotestosterone.
antihyperplasia drug	A drug used for the treatment of hyperplasia (increaced cell production within an organ or tissue).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
aza-steroid	An aza-steroid is a steroid where in the carbon skeleton a carbon atom is replaced by nitrogen.
3-oxo steroid	Any oxo steroid where an oxo substituent is located at position 3.
delta-lactam	A lactam in which the amide bond is contained within a six-membered ring, which includes the amide nitrogen and the carbonyl carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	51.4296	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	45.2716	0.1737	34.3047	61.8120	AID1346859; AID1346924
SMAD family member 3	Homo sapiens (human)	Potency	45.2716	0.1737	34.3047	61.8120	AID1346859; AID1346924
TDP1 protein	Homo sapiens (human)	Potency	8.9215	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	4.5003	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	24.1133	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743042; AID743063
progesterone receptor	Homo sapiens (human)	Potency	51.9620	0.0004	17.9460	75.1148	AID1346795
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	44.4311	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	21.7284	0.0008	17.5051	59.3239	AID1159527
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	42.2416	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	30.3396	0.3758	27.4851	61.6524	AID743217; AID743220
pregnane X nuclear receptor	Homo sapiens (human)	Potency	58.1904	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	48.1948	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080
G	Vesicular stomatitis virus	Potency	0.8709	0.0123	8.9648	39.8107	AID1645842
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	8.6171	0.0010	24.5048	61.6448	AID743212
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	6.8448	0.0237	23.2282	63.5986	AID743222
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	51.7026	19.7391	45.9784	64.9432	AID1159509
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	45.5591	0.0003	23.4451	159.6830	AID743065; AID743066; AID743067
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	6.3096	0.0398	16.7842	39.8107	AID1454
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	48.0193	0.0006	27.2152	1,122.0200	AID743202; AID743219
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	3.9811	0.0079	8.2332	1,122.0200	AID2551
geminin	Homo sapiens (human)	Potency	14.1837	0.0046	11.3741	33.4983	AID624296; AID624297
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	60.4474	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	0.8709	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	0.8709	0.0123	8.9648	39.8107	AID1645842
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	60.4474	0.0015	51.7393	15,848.9004	AID1259244
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	0.8709	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	0.8709	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	51.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	28.2000	0.1100	7.1903	10.0000	AID1443980; AID1443989; AID1473738
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	2.0000	0.0000	2.8005	10.0000	AID625248
Androgen receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	100.0000	0.0010	1.9794	14.1600	AID39178
3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)	IC50 (µMol)	2.4910	0.0017	0.4880	7.5000	AID1272918; AID1573001; AID1573006; AID1573008; AID1803328; AID207453; AID207454; AID207456; AID207459; AID207596; AID207758; AID207759; AID207760; AID207765; AID207913; AID207914; AID207916; AID215796; AID242533; AID299269; AID703695; AID91250
3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)	Ki	0.2580	0.0050	0.5303	1.6000	AID207887; AID207919
3-oxo-5-alpha-steroid 4-dehydrogenase 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	180.0078	0.0042	7.4680	21.1000	AID1166503; AID1263196; AID1573010; AID207301; AID207604
3-oxo-5-alpha-steroid 4-dehydrogenase 1	Rattus norvegicus (Norway rat)	Ki	0.0595	0.0050	0.0401	0.0882	AID207426; AID207427; AID207595
3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)	IC50 (µMol)	24.2434	0.0001	0.5267	10.0000	AID1166503; AID1272903; AID1573000; AID1573007; AID1573009; AID1803329; AID205601; AID205602; AID205603; AID207440; AID207441; AID207443; AID207446; AID207613; AID207734; AID207735; AID207924; AID215799; AID227856; AID242430; AID299270; AID703552; AID91252
3-oxo-5-alpha-steroid 4-dehydrogenase 2	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.3286	0.0003	7.3294	21.1000	AID1573011; AID207301; AID207451; AID207902; AID597647
3-oxo-5-alpha-steroid 4-dehydrogenase 2	Rattus norvegicus (Norway rat)	Ki	0.0770	0.0050	1.7110	10.0000	AID207426; AID207427
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	1.0000	0.0000	2.3983	10.0000	AID625247
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
steroid biosynthetic process	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
androgen biosynthetic process	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
estrogen biosynthetic process	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
hippocampus development	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
C21-steroid hormone metabolic process	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
response to corticosterone	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
urogenital system development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
liver development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
androgen biosynthetic process	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
androgen catabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
sex determination	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
male gonad development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
cellular response to starvation	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
response to xenobiotic stimulus	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
response to muscle activity	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
diterpenoid metabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
spinal cord development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
hippocampus development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
thalamus development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
hypothalamus development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
pituitary gland development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
cerebral cortex development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
cell differentiation	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
male genitalia development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
female genitalia development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
response to follicle-stimulating hormone	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
cellular response to insulin stimulus	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
serotonin metabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
progesterone metabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
response to estrogen	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
bone development	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
response to growth hormone	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
response to fungicide	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
cellular response to cAMP	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
cellular response to growth factor stimulus	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
cellular response to estradiol stimulus	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
cellular response to testosterone stimulus	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
cellular response to dexamethasone stimulus	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
cellular response to epinephrine stimulus	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
steroid biosynthetic process	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
androgen biosynthetic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
steroid catabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
cell-cell signaling	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
androgen metabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
male gonad development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to xenobiotic stimulus	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
biphenyl metabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
phthalate metabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
hippocampus development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
hypothalamus development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
cell differentiation	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
male genitalia development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
female genitalia development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to nutrient levels	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to follicle-stimulating hormone	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to testosterone	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to peptide hormone	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to steroid hormone	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
bone development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
testosterone biosynthetic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
steroid biosynthetic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
3-keto sterol reductase activity	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
3-beta-hydroxy-delta5-steroid dehydrogenase activity	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
steroid delta-isomerase activity	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
protein binding	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activity	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
3-oxo-5-alpha-steroid 4-dehydrogenase activity	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
electron transfer activity	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
amide binding	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) activity	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
NADPH binding	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
3-oxo-5-alpha-steroid 4-dehydrogenase activity	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
protein binding	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activity	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
amide binding	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) activity	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
nucleolus	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
mitochondrial inner membrane	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
mitochondrial intermembrane space	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
endoplasmic reticulum	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
endoplasmic reticulum membrane	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
smooth endoplasmic reticulum membrane	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
intercellular bridge	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
intracellular membrane-bounded organelle	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
cytoplasm	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Homo sapiens (human)
endoplasmic reticulum membrane	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
neuronal cell body	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
perinuclear region of cytoplasm	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
cell body fiber	3-oxo-5-alpha-steroid 4-dehydrogenase 1	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
neuronal cell body	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
cell body fiber	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID550804	Inhibition of human prostate 5alpha-reductase type 2 assessed as formation dihydrotestosterone from [4-14C] testosterone	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID774937	Inhibition of testosterone propionate-induced prostate hyperplasia in Wistar rat assessed as ratio of prostate weight to body weight at 5 mg/kg, ip co-administered with testosterone propionate for 14 days (Rvb = 3.1634 +/- 0.1264 no unit)	2013	European journal of medicinal chemistry, Nov, Volume: 69	Identification and characterization of novel indole based small molecules as anticancer agents through SIRT1 inhibition.
AID678721	Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID703549	Anti-benign prostatic hyperplasia activity in Wistar rat assessed as reduction of body weight gain at 1 mg/kg, po qd for 14 days measured on day 15	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1217653	Renal clearance in castrated pig at 0.8 mg/kg, administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID205603	In vitro inhibitory activity against human type 2 5-alpha reductase	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID207916	Inhibitory activity against 5-alpha-reductase type 1 in cell culture system using LNCaP cells (androgen-sensitive human prostatic cancer cell line)	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	A novel class of inhibitors for steroid 5alpha-reductase: synthesis and evaluation of umbelliferone derivatives.
AID207887	Inhibitory activity against recombinant Steroid 5-alpha-reductase type I expressed in CHO cells	2000	Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20	Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID20789	Bioavailability in dog (male Beagle) i.v. administration	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.
AID486431	Antiproliferative activity against human DU145 cells assessed as growth inhibition at 2 ug/mL after 48 hrs by MTT assay relative to control	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams.
AID174355	Percent conversion of testosterone to dihydrotestosterone in prostate of rats at 10 mg/kg of compound given perorally	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole derivatives as a new class of steroid 5 alpha-reductase inhibitors.
AID1573010	Inhibition of type 1 5alpha reductase in rat prostate	2018	Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1272914	Decrease in ventral prostate organ weight in male wistar rat at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID1225523	Reduction in proliferating cell nuclear antigen expression in prostate tissue in BPH-induced Sprague-Dawley rat model at 5 mg/kg, po daily for 4 weeks by Western blot analysis	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Effects of resveratrol on benign prostatic hyperplasia by the regulation of inflammatory and apoptotic proteins.
AID242448	Displacement of [3H]R-1881 from Androgen receptor of PC3-AR cells; - = not determined	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
AID1263206	Increase of diameter of pigmented spot of flank organs in gonadectomized golden hamster at 1 mg/kg, sc qd for 6 days co-administered with 1 mg/kg of testosterone (Rvb = 2.03 +/- 0.63 millimeter)	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
AID207919	Binding affinity for human 5 alpha reductase 1 isozyme	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Pharmacological options in the treatment of benign prostatic hyperplasia.
AID299270	Inhibition of steroid 5-alpha reductase type 2 expressed in HEK 293 cells	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Evaluation of 4'-substituted bicyclic pyridones as non-steroidal inhibitors of steroid 5alpha-reductase.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1217615	Cmax in castrated pig plasma withdrawn from hepatic vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID524794	Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1489058	Elimination half-life in Sprague-Dawley rat at 0.2 mg/kg, po by LC-MS/MS analysis	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1263193	Cytotoxicity against human PC3 cells assessed as growth inhibition at 50 uM	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
AID1489054	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473832	Ratio of drug concentration at steady state in human in alopecia patient at 1 mg, po QD after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID597653	Inhibition of testosterone propionate-induced castrated Wistar rat benign prostatic hyperplasia model assessed as prostate gland arrangement order at 10 mg/kg, iv by histochemistry	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Synthesis and bioactivity of new Finasteride conjugate.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1217614	Cmax in castrated pig plasma withdrawn from portal vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217687	Apparent biliary clearance in castrated pig at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID486433	Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams.
AID1487741	Decrease in progesterone level in human MCF7 cells at 1 to 10 uM after 24 hrs by ELISA	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	Targeting progesterone metabolism in breast cancer with l-proline derived new 14-azasteroids.
AID1217583	Terminal half life in castrated pig plasma withdrawn from hepatic vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1515146	Antagonist activity at alpha1 androgen receptor (unknown origin) assessed as reduction in R1881-induced response at 10 uM by dual-luciferase reporter gene assay relative to control	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
AID1217680	Liver extraction ratio in castrated pig at 0.2 mg/kg, iv measured based on clearance by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1272905	Increase in body weight gain in male wistar rat at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose (Rvb=9.412+/-1.632g%)	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID17979	Bioavailability in dog (Beagle) at t1/2 (dose 5 mg/kg i.v.)	1995	Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14	Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
AID207596	Compound was evaluated for the inhibition of human Steroid 5-alpha-reductase type 1 from recombinant CHO cells	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis of benzo[c]quinolizin-3-ones: selective non-steroidal inhibitors of steroid 5 alpha-reductase 1.
AID1217558	Biliary excretion in castrated pig assessed as unchanged drug level at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1601345	Antagonist activity at androgen receptor (unknown origin) assessed as inhibition of R1881-induced receptor transactivation at 10 uM by dual-luciferase reporter gene assay relative to control	2019	Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20	Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
AID774928	Inhibition of testosterone propionate-induced prostate hyperplasia in Wistar rat assessed as retention of normal cell morphology at 5 mg/kg, ip co-administered with testosterone propionate for 14 days by hematoxylin/eosin staining method	2013	European journal of medicinal chemistry, Nov, Volume: 69	Identification and characterization of novel indole based small molecules as anticancer agents through SIRT1 inhibition.
AID23617	Plasma half life in beagles after iv administration of 5 mg/kg.	1995	Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14	Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1515144	Antiproliferative activity against human LNCAP cells after 24 hrs by CCK-8 assay	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
AID39178	In vitro antagonist activity against rat prostatic androgen receptor (AR)	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding.
AID468985	Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID1217650	Drug excretion in castrated pig urine assessed as fraction of the dose excreted at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217661	AUC (0 to 6 hrs) in castrated pig plasma withdrawn from portal vein at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217587	Absorption rate constant in castrated pig plasma withdrawn from portal vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217559	Biliary excretion in castrated pig assessed as unchanged drug level at 0.2 mg/kg, iv measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217611	AUC (0 to 6 hrs) in castrated pig plasma withdrawn from portal vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1217565	Drug metabolism in castrated pig plasma withdrawn from portal vein assessed as omega-hydroxy finasteride metabolite formation by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1272906	Effect on organ weight in male wistar rat assessed as liver tissue weight per 100g at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose (Rvb=2.994+/- 0.254 g/100g)	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID774935	Inhibition of testosterone propionate-induced prostate hyperplasia in Wistar rat at 5 mg/kg, ip co-administered with testosterone propionate for 14 days	2013	European journal of medicinal chemistry, Nov, Volume: 69	Identification and characterization of novel indole based small molecules as anticancer agents through SIRT1 inhibition.
AID486428	Antiproliferative activity against human DU145 cells assessed as growth inhibition at 0.01 ug/mL after 48 hrs by MTT assay relative to control	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams.
AID597648	Toxicity in testosterone propionate-induced castrated Wistar rat benign prostatic hyperplasia model assessed as body weight at 2 to 50 mg/kg, iv for 14 days	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Synthesis and bioactivity of new Finasteride conjugate.
AID748445	Half life in human liver microsomes at 1 uM in presence of NADPH	2013	ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6	Metabolically Stable tert-Butyl Replacement.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1272903	Inhibition of human 5alpha-2 reductase expressed in HEK293 cells assessed as suppression of conversion of [3]androstenedione incubated for 30 mins by radioactivity-based HPLC analysis	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID597655	Inhibition of testosterone propionate-induced castrated Wistar rat benign prostatic hyperplasia model assessed as decrease in epithelial protrusions at 10 mg/kg, iv by histochemistry	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Synthesis and bioactivity of new Finasteride conjugate.
AID1713216	Antiproliferative activity against androgen-sensitive human LNCAP cells assessed as inhibition of cell growth at 50 uM incubated for 48 hrs by sulforhodamine B assay relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their anti-proliferative effect on human androgen-sensitive LNCaP cell line.
AID1263200	Increase of prostate weight in gonadectomized golden hamster at 1 mg/kg, sc qd for 6 days co-administered with 1 mg/kg of testosterone (Rvb = 50.4 +/- 9.9 mg)	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
AID703547	Anti-benign prostatic hyperplasia activity in Wistar rat assessed as reduction of dorsal prostate weight gain at 1 mg/kg, po qd for 14 days measured on day 15	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID207456	In vitro inhibition of human steroid 5-alpha-reductase type I in Du-145 cells	1995	Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7	Synthesis and in vitro activity of 17 beta-(N-alkyl/arylformamido)- and 17 beta-[(N-alkyl/aryl)alkyl/arylamido]-4-methyl-4-aza-3-oxo-5 alpha-androstan-3-ones as inhibitors of human 5 alpha-reductases and antagonists of the androgen receptor.
AID1489056	Growth inhibition of human PC3 cells at 80 uM after 48 hrs by MTT assay relative to control	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
AID1217567	Drug metabolism in castrated pig plasma withdrawn from hepatic vein assessed as omega-hydroxy finasteride metabolite formation by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1272908	Effect on organ weight in male wistar rat assessed as dorsal prostate tissue weight per 100g at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose (Rvb=50.325+/-7.519 mg/100g)	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID703548	Anti-benign prostatic hyperplasia activity in Wistar rat assessed as reduction of ventral prostate weight gain at 1 mg/kg, po qd for 14 days measured on day 15	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID207446	Inhibitory activity measured on human steroid 5-alpha-reductase type 2	1995	Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14	Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
AID1601347	Antiproliferative activity against AR-rich human LNCaP-hr cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	2019	Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20	Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
AID1166505	Displacement of [3H]MIB from rat prostate cytosol androgen receptor at 1x10'-10 to 1x10'-7 M relative to control	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3.
AID215796	Compound was tested for inhibition of Type I 5-alpha-reductase in Human genital skin (Hs68) foreskin fibroblast cells.	1993	Journal of medicinal chemistry, Feb-05, Volume: 36, Issue:3	Nonsteroidal inhibitors of human type I steroid 5-alpha-reductase.
AID703545	Anti-benign prostatic hyperplasia activity in Wistar rat assessed as reduction of testis weight gain per 100 gram of body weight at 1 mg/kg, po qd for 14 days measured on day 15	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID1263207	Increase of seminal vesicles weight in gonadectomized golden hamster at 1 mg/kg, sc qd for 6 days co-administered with 1 mg/kg of testosterone (Rvb = 96.11 +/- 12.5 mg)	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
AID1217679	Hepatic clearance in castrated pig at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1272915	Decrease in dorsal prostate organ weight in male wistar rat at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID1806971	In vivo inhibition of PNMT in Sprague-Dawley rat assessed as decrease in epinephrine level in adrenal gland at 1 mg, sc once daily treated for 20 days and measured after 24 hrs post last dose by liquid chromatography tandem mass spectrometry analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1651800	Suppression of serum DHT level in Sprague-Dawley rat model of testosterone propionate-induced benign prostatic hyperplasia at 10 mg/kg, po by ELISA	2020	Journal of natural products, 04-24, Volume: 83, Issue:4	Oleanolic Acid Ameliorates Benign Prostatic Hyperplasia by Regulating PCNA-Dependent Cell Cycle Progression
AID1217646	Drug excretion in castrated pig urine assessed as unchanged drug level at 0.8 mg/kg administered as intrajejunal dose measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217685	Biliary excretion in castrated pig assessed as fraction of the dose excreted at 0.2 mg/kg, iv measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1489059	Tmax in Sprague-Dawley rat at 0.2 mg/kg, po by LC-MS/MS analysis	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
AID1573007	Inhibition of human type 2 5alpha reductase	2018	Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1217688	Apparent biliary clearance in castrated pig at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1869222	Suppression of testosterone propionate induced 5AR2 expression in human LNCaP cells pretreated with TP for 1 hr followed by compound addition at 10 uM by Western blotting analysis	2022	Journal of natural products, 06-24, Volume: 85, Issue:6	Voratins A-C: Pyridinium Alkaloids from the Marine Dinoflagellate
AID1217622	Tmax in castrated pig plasma withdrawn from femoral vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID703552	Inhibition of human type-2 5-alpha reductase expressed in HEK293 cells using [3H]-androstenedione as substrate after 30 mins by HPLC analysis	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID1217557	Biliary excretion in castrated pig assessed as unchanged drug level at 0.8 mg/kg administered as intrajejunal dose measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID207459	Inhibition of recombinant human Steroid 5-alpha-reductase type I	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	4-Aza-3-oxo-5 alpha-androst-1-ene-17 beta-N-aryl-carboxamides as dual inhibitors of human type 1 and type 2 steroid 5 alpha-reductases. Dramatic effect of N-aryl substituents on type 1 and type 2 5 alpha-reductase inhibitory potency.
AID207604	Compound was tested for the inhibitory activity against Steroid 5-alpha-reductase type 1 in rat	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Structure activity relationship study of known inhibitors of the enzyme 5 alpha-reductase (5AR).
AID207608	Compound was evaluated for the inhibition of human Steroid 5-alpha-reductase type 2 receptor from human prostate homogenates	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis of benzo[c]quinolizin-3-ones: selective non-steroidal inhibitors of steroid 5 alpha-reductase 1.
AID1217693	Cmax in castrated pig bile at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID207595	Inhibition of recombinant Steroid 5-alpha-reductase type I was evaluated as binding affinity (in vitro)	1995	Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14	Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
AID1217579	Terminal half life in castrated pig plasma withdrawn from portal vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217585	Absorption rate constant in castrated pig plasma withdrawn from portal vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID207285	Ratio of IC50 to that of 10x compound against Steroid 5-alpha-reductase	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding.
AID207913	Inhibition of type 1 steroid-5-alpha-reductase	1994	Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23	4,7 beta-Dimethyl-4-azacholestan-3-one (MK-386) and related 4-azasteroids as selective inhibitors of human type 1 5 alpha-reductase.
AID1651810	Induction of PARP1 cleavage in prostate tissue of Sprague-Dawley rat model of testosterone propionate-induced benign prostatic hyperplasia at 10 mg/kg, po by Western blot analysis	2020	Journal of natural products, 04-24, Volume: 83, Issue:4	Oleanolic Acid Ameliorates Benign Prostatic Hyperplasia by Regulating PCNA-Dependent Cell Cycle Progression
AID1489049	Inhibition of rat liver 5alpha-reductase using testosterone as substrate incubated for 30 mins measured for 10 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
AID207427	Ability to inhibit Steroid 5-alpha-reductase in rat using Isotope method [3H]T to [3H]-DHT]	1998	Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15	A practical synthesis of 3-substituted delta 3,5(6)-steroids as new potential 5 alpha-reductase inhibitor.
AID242430	Inhibition of [1-beta-2beta-3H]- -testosterone binding to human steroid 5-alpha-reductase type 2 of BPH tissue at 10 uM	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
AID524791	Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1397332	Inhibition of testosterone-induced flank organ enlargement in golden hamster assessed as reduction in diameter of pigmented spot at 1 mg/kg, sc administered daily for 6 days measured post last dose by calliper method	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Activity of steroid 4 and derivatives 4a-4f as inhibitors of the enzyme 5α-reductase 1.
AID207735	Inhibition of Steroid 5-alpha-reductase type 2 from human benign prostatic hyperplasia (BPH) tissue	2002	Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16	Synthesis and evaluation of 2'-substituted 4-(4'-carboxy- or 4'-carboxymethylbenzylidene)-N-acylpiperidines: highly potent and in vivo active steroid 5alpha-reductase type 2 inhibitors.
AID207440	In vitro inhibition of human steroid 5-alpha-reductase type 2 in SW-13-transfected cells	1995	Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7	Synthesis and in vitro activity of 17 beta-(N-alkyl/arylformamido)- and 17 beta-[(N-alkyl/aryl)alkyl/arylamido]-4-methyl-4-aza-3-oxo-5 alpha-androstan-3-ones as inhibitors of human 5 alpha-reductases and antagonists of the androgen receptor.
AID1217616	Cmax in castrated pig plasma withdrawn from femoral vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID207441	In vitro inhibition of human Steroid 5-alpha-reductase type 2 in transfected SW-13 cells using [3H]- delta4-Androstenedione as substrate	1995	Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9	Synthesis and in vitro evaluation of 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17 beta-carboxamides as 5 alpha-reductase inhibitors and antiandrogens.
AID1217676	Liver extraction ratio in castrated pig at 0.8 mg/kg, administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1397340	Inhibition of testosterone-induced increase in seminal vesicle weight in golden hamster at 1 mg/kg, sc administered daily for 6 days measured post last dose	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Activity of steroid 4 and derivatives 4a-4f as inhibitors of the enzyme 5α-reductase 1.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1217677	Hepatic clearance in castrated pig at 0.8 mg/kg, administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1806970	In vivo inhibition of PNMT in Sprague-Dawley rat assessed as increase in norepinephrine level in adrenal gland at 1 mg, sc administered once daily for 20 days and measured after 24 hrs post last dose by liquid chromatography tandem mass spectrometry analy	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target.
AID1651802	Suppression of 5-alpha reductase2 mRNA expression in Sprague-Dawley rat model of testosterone propionate-induced benign prostatic hyperplasia at 10 mg/kg, po by qRT-PCR method	2020	Journal of natural products, 04-24, Volume: 83, Issue:4	Oleanolic Acid Ameliorates Benign Prostatic Hyperplasia by Regulating PCNA-Dependent Cell Cycle Progression
AID207453	Binding affinity to recombinant human Steroid 5-alpha-reductase type I was evaluated	1995	Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14	Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
AID1601346	Antiproliferative activity against AR-deficient human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	2019	Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20	Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
AID1217654	Renal clearance in castrated pig at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID703550	Toxicity in Wistar rat assessed as mortality at 1 mg/kg, po qd for 14 days measured on day 15	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID1443989	Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell plasma membrane vesicles assessed as reduction in ATP-dependent [3H]-taurocholate uptake in to vesicles preincubated for 10 mins followed by ATP addition measured after 10 to	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1217695	Ratio of AUC in bile to plasma withdrawn from portal vein in castrated pig at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID353555	Inhibition of 5-alpha-reductase in rat liver microsome assessed as conversion of [14C] testosterone to [14C] dihydrotestosterone	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
AID1217560	Fraction unbound in pig plasma	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID207898	Compound was tested in vitro for inhibitory activity against 5-alpha reductase isozyme homogenated from transfected Namalwa	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole derivatives as a new class of steroid 5 alpha-reductase inhibitors.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID207893	Inhibition of Steroid 5-alpha-reductase type I from rat ventral prostate (RVP)	2002	Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16	Synthesis and evaluation of 2'-substituted 4-(4'-carboxy- or 4'-carboxymethylbenzylidene)-N-acylpiperidines: highly potent and in vivo active steroid 5alpha-reductase type 2 inhibitors.
AID1217663	AUC (0 to 6 hrs) in castrated pig plasma withdrawn from femoral vein at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217609	AUC (0 to 6 hrs) in castrated pig plasma withdrawn from hepatic vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217561	Volume of distribution at steady state in human	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217651	Drug excretion in castrated pig urine assessed as fraction of the dose excreted at 0.2 mg/kg, iv measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID591082	Inhibition of Mycobacterium tuberculosis 3 beta hydroxysteriod dehydrogenase	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Inhibition of the M. tuberculosis 3β-hydroxysteroid dehydrogenase by azasteroids.
AID1217678	Liver extraction ratio in castrated pig at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1166507	Cytotoxicity against Swiss mouse primary peritoneal macrophages assessed as growth inhibition at 50 uM after 48 hrs by SRB assay	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3.
AID1263194	Cytotoxicity against human MCF7 cells as growth inhibition at 50 uM	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
AID1473826	AUC in alopecia patient at 1 mg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1217613	AUC (0 to 6 hrs) in castrated pig plasma withdrawn from femoral vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1489061	AUC (0 to t) in Sprague-Dawley rat at 0.2 mg/kg, po by LC-MS/MS analysis	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
AID1272911	Effect on organ weight in male wistar rat assessed as adrenal tissue weight per 100g at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose (Rvb=14.762 +/-0.600 mg/100g)	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID242533	Inhibition of [1-beta-3H]-androstenedione binding to human steroid 5-alpha-reductase type I expressed in DU-145 cells at 10 uM	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
AID1651795	Suppression of prostate tissue weight in Sprague-Dawley rat model of testosterone propionate-induced benign prostatic hyperplasia at 10 mg/kg, po relative to control	2020	Journal of natural products, 04-24, Volume: 83, Issue:4	Oleanolic Acid Ameliorates Benign Prostatic Hyperplasia by Regulating PCNA-Dependent Cell Cycle Progression
AID1217686	Apparent biliary clearance in castrated pig at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID597646	Inhibition of testosterone propionate-induced castrated Wistar rat benign prostatic hyperplasia model assessed as decrease in seminal vesicles weight at 10 mg/kg, iv for 14 days	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Synthesis and bioactivity of new Finasteride conjugate.
AID1487743	Decrease in 5alpha-DHP level in human MCF7 cells at 1 to 10 uM after 24 hrs by ELISA	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	Targeting progesterone metabolism in breast cancer with l-proline derived new 14-azasteroids.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473827	AUC in benign prostate hyperplasia patient at 5 mg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1217610	AUC (0 to 6 hrs) in castrated pig plasma withdrawn from femoral vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID597654	Inhibition of testosterone propionate-induced castrated Wistar rat benign prostatic hyperplasia model assessed as decrease in pseudostratified epithelia at 10 mg/kg, iv by histochemistry	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Synthesis and bioactivity of new Finasteride conjugate.
AID207740	Inhibitory activity against steroid 5-alpha-reductase type 2 in human prostate homogenates	2000	Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20	Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1515143	Antiproliferative activity against human DU145 cells after 24 hrs by CCK-8 assay	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
AID91252	Inhibition of recombinant human 5-alpha reductase-2 at a concentration of 5 microL after pre-incubation for 10 minutes	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductase.
AID207765	Inhibitory concentration against human recombinant steroid 5-alpha-reductase type I in stably transfected chinese hamster ovary (CHO) 1827 cells using [3H]testosterone.	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	Synthesis, biological activity, and three-dimensional quantitative structure-activity relationship model for a series of benzo[c]quinolizin-3-ones, nonsteroidal inhibitors of human steroid 5alpha-reductase 1.
AID1217683	Biliary excretion in castrated pig assessed as fraction of the dose excreted at 0.8 mg/kg administered as intrajejunal dose measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1651808	Downregulation of prostate Bcl-xL expression in Sprague-Dawley rat model of testosterone propionate-induced benign prostatic hyperplasia at 10 mg/kg, po by Western blot analysis	2020	Journal of natural products, 04-24, Volume: 83, Issue:4	Oleanolic Acid Ameliorates Benign Prostatic Hyperplasia by Regulating PCNA-Dependent Cell Cycle Progression
AID1217582	Terminal half life in castrated pig plasma withdrawn from portal vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1263197	Inhibition of human prostate type 2 5alpha-reductase assessed as transformation of testosterone to dihydrotestosterone	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
AID207613	Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type 2 from human BPH tissue at 210 nM of testosterone	2000	Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22	Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
AID442239	Inhibition of human 5 alpha reductase assessed as -log of ratio of IC50 of drug to the IC50 of reference compound	2010	European journal of medicinal chemistry, Feb, Volume: 45, Issue:2	3D-QSAR studies on unsaturated 4-azasteroids as human 5alpha-reductase inhibitors: a self organizing molecular field analysis approach.
AID1713217	Antiproliferative activity against androgen-sensitive human LNCAP cells assessed as inhibition of testosterone-induced cell growth at 50 uM incubated for 48 hrs by sulforhodamine B assay relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their anti-proliferative effect on human androgen-sensitive LNCaP cell line.
AID1713218	Antiproliferative activity against androgen-sensitive human LNCAP cells assessed as inhibition of DHT-induced cell growth at 50 uM incubated for 48 hrs by sulforhodamine B assay relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their anti-proliferative effect on human androgen-sensitive LNCaP cell line.
AID486432	Antiproliferative activity against human DU145 cells assessed as growth inhibition at 5 ug/mL after 48 hrs by MTT assay relative to control	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams.
AID91250	Inhibition of recombinant human 5-alpha reductase-1 at a concentration of 5 microL after pre-incubation for 10 minutes	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductase.
AID1217697	Ratio of AUC in bile to plasma withdrawn from portal vein in castrated pig at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217664	Apparent half-life of the terminal disposition phase in castrated pig plasma withdrawn from portal vein at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217689	AUC (0 to 6 hrs) in castrated pig bile at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID3436	Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase	1995	Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14	Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
AID1573011	Inhibition of type 2 5alpha reductase in rat prostate	2018	Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID1473831	Ratio of drug concentration at steady state in human in benign prostate hyperplasia patient at 5 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1487740	Decrease in SRD5A1 level in human MCF7 cells at 1 to 10 uM after 24 hrs by ELISA	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	Targeting progesterone metabolism in breast cancer with l-proline derived new 14-azasteroids.
AID174356	Percent conversion of testosterone to dihydrotestosterone in prostate of rats at 1 mg/kg of compound given perorally	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole derivatives as a new class of steroid 5 alpha-reductase inhibitors.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID205602	Inhibition of type 2 steroid-5-alpha-reductase	1994	Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23	4,7 beta-Dimethyl-4-azacholestan-3-one (MK-386) and related 4-azasteroids as selective inhibitors of human type 1 5 alpha-reductase.
AID1225517	Reduction in prostate weight in BPH-induced Sprague-Dawley rat model at 5 mg/kg, po daily for 4 weeks in presence testosterone propionate of 10 mg/kg, intramuscular injection for 4 weeks	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Effects of resveratrol on benign prostatic hyperplasia by the regulation of inflammatory and apoptotic proteins.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1377312	Inhibition of Francisella tularensis FabI enoyl reductase assessed as dissociation half life preincubated for 5 hrs in presence of NADH followed by crotonyl-CoA substrate addition by spectrophotometric method	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Covalent inhibitors design and discovery.
AID1217580	Terminal half life in castrated pig plasma withdrawn from hepatic vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217620	Tmax in castrated pig plasma withdrawn from portal vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID207914	In vitro inhibitory activity against human type 1 5-alpha reductase	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID703542	Anti-benign prostatic hyperplasia activity in Wistar rat assessed as reduction of epididymis weight gain at 1 mg/kg, po qd for 14 days measured on day 15	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID1573006	Inhibition of human type 1 5alpha reductase	2018	Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID1217691	AUC (0 to 6 hrs) in castrated pig bile at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1272910	Effect on organ weight in male wistar rat assessed testis tissue weight per 100g at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose (Rvb=1054.099+/- 55.648 mg/100g)	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID1217627	Ratio of drug level in blood to plasma in human measured after 30 to 300 mins by HPLC-UV analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID189540	% reduction in prostate weight when compared with T-treated controls was measured in castrated rat at 10 mg/kg/day po administration	1995	Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14	Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
AID1217647	Drug excretion in castrated pig urine assessed as unchanged drug level at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217681	Liver extraction ratio in castrated pig at 0.2 mg/kg, iv measured based on AUC by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217568	Drug excretion in castrated pig bile assessed as omega-hydroxy finasteride metabolite formation by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1489050	Inhibition of rat liver 5alpha-reductase at 50 uM using testosterone as substrate incubated for 30 mins measured for 10 mins by fluorescence assay relative to control	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
AID1217584	Terminal half life in castrated pig plasma withdrawn from femoral vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID205608	Inhibitory activity against 5-alpha Reductase-2 on human prostate homogenates from surgically derived benign hyperplastic tissue	1997	Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7	19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
AID1443991	Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1217566	Drug metabolism in castrated pig plasma withdrawn from femoral vein assessed as omega-hydroxy finasteride metabolite formation by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID188534	In vivo evaluation in chronic castrated rat to inhibit T-stimulated prostate growth expressed as percentage reduction	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductase.
AID207443	Inhibition of recombinant human Steroid 5-alpha-reductase type 2	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	4-Aza-3-oxo-5 alpha-androst-1-ene-17 beta-N-aryl-carboxamides as dual inhibitors of human type 1 and type 2 steroid 5 alpha-reductases. Dramatic effect of N-aryl substituents on type 1 and type 2 5 alpha-reductase inhibitory potency.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1217698	Ratio of AUC in bile to plasma withdrawn from hepatic vein in castrated pig at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID3228	Binding affinity for 3-beta-hydroxysteroid dehydrogenase	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Pharmacological options in the treatment of benign prostatic hyperplasia.
AID1573000	Inhibition of human type 2 5alpha reductase expressed in HEK293 cells	2018	Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID174357	Percent conversion of testosterone to dihydrotestosterone in prostate of rats at 30 mg/kg of compound given perorally	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole derivatives as a new class of steroid 5 alpha-reductase inhibitors.
AID1217696	Ratio of AUC in bile to plasma withdrawn from portal vein in castrated pig at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID703541	Anti-benign prostatic hyperplasia activity in Wistar rat assessed as reduction of liver weight gain per 100 gram of body weight at 1 mg/kg, po qd for 14 days measured on day 15	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID1217586	Absorption rate constant in castrated pig plasma withdrawn from femoral vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID307900	Inhibition of steroid 5-alpha-reductase activity in Sprague-Dawley rat liver microsomes after 10 mins	2007	Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14	The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1272909	Effect on organ weight in male wistar rat assessed as seminal vesicles tissue weight per 100g at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose (Rvb=175.439+/-12.833 mg/100g)	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1263196	Inhibition of rat liver type 1 5alpha-reductase assessed as transformation of testosterone to dihydrotestosterone	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26442	Half-life after intravenous administration of 10 mg/kg/day dose in male beagles	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.
AID1573009	Inhibition of type 2 5alpha reductase in human prostate	2018	Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID1166506	Cytotoxicity against human PC3 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3.
AID1217694	Cmax in castrated pig bile at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473830	Ratio of drug concentration at steady state in human in alopecia patient at 1 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1217608	AUC (0 to 6 hrs) in castrated pig plasma withdrawn from portal vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1473829	Drug concentration at steady state in benign prostate hyperplasia patient at 5 mg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID188535	In vivo inhibition of T stimulated prostate growth in rats was reported after oral administration at a dose 10 mg/kg/day	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.
AID1391633	Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by CCK8 assay
AID1217569	Drug excretion in castrated pig urine assessed as omega-hydroxy finasteride metabolite formation by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID207900	Inhibitory activity of compound towards 5-alpha reductase from rat at 100 nM concentration	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole derivatives as a new class of steroid 5 alpha-reductase inhibitors.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1473828	Drug concentration at steady state in alopecia patient at 1 mg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1651807	Downregulation of prostate Bcl2 expression in Sprague-Dawley rat model of testosterone propionate-induced benign prostatic hyperplasia at 10 mg/kg, po by Western blot analysis	2020	Journal of natural products, 04-24, Volume: 83, Issue:4	Oleanolic Acid Ameliorates Benign Prostatic Hyperplasia by Regulating PCNA-Dependent Cell Cycle Progression
AID1806972	Effect on PNMT protein expression level in Sprague-Dawley rat at 1 mg, sc once daily treated for 20 days and measured after 24 hrs post last dose by western blot analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID174354	Percent conversion of testosterone to dihydrotestosterone in prostate of rats at 0 mg/kg of compound given perorally	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole derivatives as a new class of steroid 5 alpha-reductase inhibitors.
AID1713219	Cytotoxicity against Wistar rat PBMC assessed as inhibition of cell growth at 50 uM incubated for 24 hrs by sulforhodamine B assay relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their anti-proliferative effect on human androgen-sensitive LNCaP cell line.
AID1869223	Suppression of testosterone propionate induced AR expression in human LNCaP cells pretreated with TP for 1 hr followed by compound addition at 10 uM by Western blotting analysis	2022	Journal of natural products, 06-24, Volume: 85, Issue:6	Voratins A-C: Pyridinium Alkaloids from the Marine Dinoflagellate
AID1217618	Cmax in castrated pig plasma withdrawn from hepatic vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1217578	Tmax in castrated pig plasma withdrawn from femoral vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID242071	In vitro inhibitory concentration against Cytochrome P450 17 expressed in E. coli; - = not determined	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
AID1217665	Apparent half-life of the terminal disposition phase in castrated pig plasma withdrawn from hepatic vein at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1443995	Hepatotoxicity in human assessed as drug-induced liver injury	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1166504	Inhibition of human prostate 5alpha-reductase type 2 assessed as conversion of [3H]testosterone to dihydrotestosterone	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3.
AID1473833	Ratio of drug concentration at steady state in human in benign prostate hyperplasia patient at 5 mg, po QD after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1489060	Cmax in Sprague-Dawley rat at 0.2 mg/kg, po by LC-MS/MS analysis	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
AID207759	Inhibition of Human steroid 5-alpha-reductase type I expressed in HEK293 cells	2000	Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22	Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID774936	Inhibition of testosterone propionate-induced prostate hyperplasia in Wistar rat assessed as seminal vesicle weight at 5 mg/kg, ip co-administered with testosterone propionate for 14 days (Rvb = 1.6071 +/- 0.0821 g)	2013	European journal of medicinal chemistry, Nov, Volume: 69	Identification and characterization of novel indole based small molecules as anticancer agents through SIRT1 inhibition.
AID227856	Inhibitory concentration against human recombinant steroid 5-alpha-reductase type 2 in stably transfected chinese hamster ovary 1827 cells using [3H]testosterone	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	Synthesis, biological activity, and three-dimensional quantitative structure-activity relationship model for a series of benzo[c]quinolizin-3-ones, nonsteroidal inhibitors of human steroid 5alpha-reductase 1.
AID1272916	Decrease in vas deferens organ weight in male wistar rat at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID174358	Percent conversion of testosterone to dihydrotestosterone in prostate of rats at 3 mg/kg of compound given perorally	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole derivatives as a new class of steroid 5 alpha-reductase inhibitors.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1272917	Decrease in epididymis organ weight in male wistar rat at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID1166503	Inhibition of rat liver 5alpha-reductase type 1 assessed as conversion of [3H]testosterone to dihydrotestosterone	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3.
AID1217617	Cmax in castrated pig plasma withdrawn from portal vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1272904	Cytotoxicity against human DU145 cells by rapid colorimetric assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID1397339	Inhibition of testosterone-induced increase in prostate weight in golden hamster at 1 mg/kg, sc administered daily for 6 days measured post last dose	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Activity of steroid 4 and derivatives 4a-4f as inhibitors of the enzyme 5α-reductase 1.
AID215799	Compound was tested for inhibition of Type II 5-alpha-reductase in Human Prostate Homogenates (HPH).	1993	Journal of medicinal chemistry, Feb-05, Volume: 36, Issue:3	Nonsteroidal inhibitors of human type I steroid 5-alpha-reductase.
AID1272912	Effect on organ weight in male wistar rat assessed as vas deferens tissue weight per 100g at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose (Rvb=67.613+/-3.248 mg/100g)	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID3435	Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase	1995	Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14	Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
AID1217699	Ratio of AUC in bile to plasma withdrawn from hepatic vein in castrated pig at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1272918	Inhibition of human 5alpha-1 reductase expressed in HEK293 cells assessed as suppression of conversion of [3]androstenedione incubated for 30 mins by radioactivity-based HPLC analysis	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID1515145	Antiproliferative activity against human RWPE1 cells after 24 hrs by CCK-8 assay	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
AID207734	Inhibition of Human steroid 5-alpha-reductase type II expressed in HEK293 cells	2000	Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22	Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
AID242435	Displacement of [3H]R-1881 from Androgen receptor of LNCaP cells; - = not determined	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
AID299269	Inhibition of steroid 5-alpha reductase type 1 expressed in HEK 293 cells	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Evaluation of 4'-substituted bicyclic pyridones as non-steroidal inhibitors of steroid 5alpha-reductase.
AID207301	In vitro inhibitory activity against rat prostatic steroid 5-alpha-reductase	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding.
AID597645	Inhibition of testosterone propionate-induced castrated Wistar rat benign prostatic hyperplasia model assessed as decrease in prostate weight at 10 mg/kg, iv for 14 days	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Synthesis and bioactivity of new Finasteride conjugate.
AID1217619	Cmax in castrated pig plasma withdrawn from femoral vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1391635	Cytotoxicity against human DU145 cells assessed as growth inhibition after 24 hrs by CCK8 assay
AID1573008	Inhibition of type 1 5alpha reductase in human prostate	2018	Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID703543	Anti-benign prostatic hyperplasia activity in Wistar rat assessed as reduction of vas deferens weight gain at 1 mg/kg, po qd for 14 days measured on day 15	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID1217563	Oral absorption in human	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1647965	Inhibition of steroid 5-alpha-reductase in human LNCAP cells assessed as reduction in 5- dihydrotestosterone formation incubated for 60 mins by LC-MS analysis	2020	Journal of natural products, 02-28, Volume: 83, Issue:2	Quintaquinone, a Merosesquiterpene from the Yellow Sponge
AID207760	In vitro inhibitory activity against Steroid 5-alpha-reductase type I of human DU 145 prostatic tumor cell line	2002	Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16	Synthesis and evaluation of 2'-substituted 4-(4'-carboxy- or 4'-carboxymethylbenzylidene)-N-acylpiperidines: highly potent and in vivo active steroid 5alpha-reductase type 2 inhibitors.
AID354805	Inhibition of 5alpha reductase from human prostatic hyperplasia	1996	Journal of natural products, May, Volume: 59, Issue:5	Determination of oenothein B as the active 5-alpha-reductase-inhibiting principle of the folk medicine Epilobium parviflorum.
AID1217621	Tmax in castrated pig plasma withdrawn from hepatic vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1217612	AUC (0 to 6 hrs) in castrated pig plasma withdrawn from hepatic vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID203349	In vitro inhibition of 5-alpha-dihydrotestosterone stimulated shionogi cell proliferation; NA is not active	1995	Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9	Synthesis and in vitro evaluation of 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17 beta-carboxamides as 5 alpha-reductase inhibitors and antiandrogens.
AID1217649	Drug excretion in castrated pig urine assessed as fraction of the dose excreted at 0.8 mg/kg administered as intrajejunal dose measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID703695	Inhibition of human type-1 5-alpha reductase expressed in HEK293 cells using [3H]-androstenedione as substrate after 30 mins by HPLC analysis	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID1443992	Total Cmax in human administered as single dose	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1515142	Antiproliferative activity against human PC3 cells after 24 hrs by CCK-8 assay	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1391634	Cytotoxicity against human LNCAP cells assessed as growth inhibition after 24 hrs by CCK8 assay
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1263195	Cytotoxicity against human SKLU1 cells as growth inhibition at 50 uM	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
AID486429	Antiproliferative activity against human DU145 cells assessed as growth inhibition at 0.5 ug/mL after 48 hrs by MTT assay relative to control	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams.
AID1217581	Terminal half life in castrated pig plasma withdrawn from femoral vein at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID273114	Ventral prostate involution in CD1 mouse at 30 mg/kg, po after 7 days	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.
AID1217577	Tmax in castrated pig plasma withdrawn from hepatic vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217684	Biliary excretion in castrated pig assessed as fraction of the dose excreted at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1489062	AUC (0 to infinity) in Sprague-Dawley rat at 0.2 mg/kg, po by LC-MS/MS analysis	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
AID1225519	Reduction in serum dihydrotestosterone in BPH-induced Sprague-Dawley rat model at 5 mg/kg, po daily for 4 weeks by ELISA	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Effects of resveratrol on benign prostatic hyperplasia by the regulation of inflammatory and apoptotic proteins.
AID1487718	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	Targeting progesterone metabolism in breast cancer with l-proline derived new 14-azasteroids.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1217692	Cmax in castrated pig bile at 0.8 mg/kg administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1272913	Effect on organ weight in male wistar rat assessed as epididymis tissue weight per 100g at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose (Rvb=187.356+/- 5.961 mg/100g)	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID207758	Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type I in human DU-145 cell assay at 5 nM of androstenedione	2000	Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22	Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
AID486438	Antiandrogenic activity in ip dosed Sprague-Dawley rat assessed as increase of serum testosterone level after 6 hrs by ELISA (Rvb = 0.742 +/- 0.07 ng/ml)	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams.
AID207454	In vitro inhibition of human Steroid 5-alpha-reductase type I in transfected 293 cells using [3H]- delta4-Androstenedione as substrate	1995	Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9	Synthesis and in vitro evaluation of 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17 beta-carboxamides as 5 alpha-reductase inhibitors and antiandrogens.
AID1217652	Renal clearance in castrated pig at 0.8 mg/kg, administered as intrajejunal dose by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217588	Absorption rate constant in castrated pig plasma withdrawn from femoral vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID468984	Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID486430	Antiproliferative activity against human DU145 cells assessed as growth inhibition at 1 ug/mL after 48 hrs by MTT assay relative to control	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams.
AID1217690	AUC (0 to 6 hrs) in castrated pig bile at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID597647	Inhibition of rat 5-alpha-reductase type 2 by Lineweaver-Burk plot	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Synthesis and bioactivity of new Finasteride conjugate.
AID3434	In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.
AID1217666	Apparent half-life of the terminal disposition phase in castrated pig plasma withdrawn from femoral vein at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1487719	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	Targeting progesterone metabolism in breast cancer with l-proline derived new 14-azasteroids.
AID1217623	Tmax in castrated pig plasma withdrawn from portal vein at 0.8 mg/kg administered as intrajejunal dose 20 mins after ketoconazole administration by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID207278	Inhibition of human steroid 5-alpha-reductase	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
AID774938	Inhibition of testosterone propionate-induced prostate hyperplasia in Wistar rat assessed as prostate weight at 5 mg/kg, ip co-administered with testosterone propionate for 14 days (Rvb = 0.838 +/- 0.0293 g)	2013	European journal of medicinal chemistry, Nov, Volume: 69	Identification and characterization of novel indole based small molecules as anticancer agents through SIRT1 inhibition.
AID1217682	Total plasma clearance in castrated pig at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217662	AUC (0 to 6 hrs) in castrated pig plasma withdrawn from hepatic vein at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1272907	Effect on organ weight in male wistar rat assessed as ventral prostate tissue weight per 100g at 5ml/kg, po qd measured on 15th day after 24 hrs of last dose (Rvb=59.494+/- 4.733 mg/100g)	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors.
AID207924	Inhibitory activity against human 5-alpha Reductase-1 expressed in DU-145 cells	1997	Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7	19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
AID207902	Compound was tested in vitro for inhibitory activity against type 2 5-alpha reductase Isozyme homogenated from rat epididymis	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole derivatives as a new class of steroid 5 alpha-reductase inhibitors.
AID1869226	Suppression of testosterone propionate induced PSA expression in human LNCaP cells pretreated with TP for 1 hr followed by compound addition at 10 uM by Western blotting analysis	2022	Journal of natural products, 06-24, Volume: 85, Issue:6	Voratins A-C: Pyridinium Alkaloids from the Marine Dinoflagellate
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID207754	Inhibition of Steroid 5-alpha-reductase type 2 of rat ventral prostate (RVP)	2002	Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16	Synthesis and evaluation of 2'-substituted 4-(4'-carboxy- or 4'-carboxymethylbenzylidene)-N-acylpiperidines: highly potent and in vivo active steroid 5alpha-reductase type 2 inhibitors.
AID774930	Inhibition of testosterone propionate-induced prostate hyperplasia in Wistar rat assessed as reduction in histoarchitecture disruption at 5 mg/kg, ip co-administered with testosterone propionate for 14 days by hematoxylin/eosin staining method	2013	European journal of medicinal chemistry, Nov, Volume: 69	Identification and characterization of novel indole based small molecules as anticancer agents through SIRT1 inhibition.
AID703546	Anti-benign prostatic hyperplasia activity in Wistar rat assessed as reduction of seminal vesicle weight gain per 100 gram of body weight at 1 mg/kg, po qd for 14 days measured on day 15	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID1263198	Displacement of [3H}-MIB from rat prostate cytosol androgen receptor assessed as relative binding affinity	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
AID1806969	Inhibition of human recombinant PNMT using AdoMet and DL-norepinephrine hydrocloride as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by fluorescence based analysis relative to control	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID207426	Ability to inhibit Steroid 5-alpha-reductase in rat using Enzyme kinetics method.	1998	Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15	A practical synthesis of 3-substituted delta 3,5(6)-steroids as new potential 5 alpha-reductase inhibitor.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID486434	Cytotoxicity against Balb/C mouse macrophages assessed as cell viability after 24 hrs by MTT assay	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams.
AID1217562	Total plasma clearance in human	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217564	Volume of distribution at steady state in castrated pig at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID703544	Anti-benign prostatic hyperplasia activity in Wistar rat assessed as reduction of adrenal weight gain per 100 gram of body weight at 1 mg/kg, po qd for 14 days measured on day 15	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
AID207451	Inhibitory activity was measured on rat Steroid 5-alpha-reductase type 2	1995	Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14	Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
AID1743297	Inhibition of 5-alpha reductase in rat liver microsomes assessed as inhibition of DHT formation using testosterone as substrate incubated for 10 mins by NADPH assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	The one-pot synthesis of butyl-1H-indol-3-alkylcarboxylic acid derivatives in ionic liquid as potent dual-acting agent for management of BPH.
AID1217700	Ratio of AUC in bile to plasma withdrawn from hepatic vein in castrated pig at 0.2 mg/kg, iv by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID1217648	Drug excretion in castrated pig urine assessed as unchanged drug level at 0.2 mg/kg, iv measured during 6 hrs sampling by UPLC-tandem mass spectrometry	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
AID205601	Binding affinity for human 5-alpha reductase 2 isozyme	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Pharmacological options in the treatment of benign prostatic hyperplasia.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1573001	Inhibition of human type 1 5alpha reductase expressed in HEK293 cells	2018	Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID524796	Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID597656	Inhibition of testosterone propionate-induced castrated Wistar rat benign prostatic hyperplasia model assessed as decrease in hyperplasia of interstitial tissues at 10 mg/kg, iv by histochemistry	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Synthesis and bioactivity of new Finasteride conjugate.
AID1489063	Retention time in Sprague-Dawley rat plasma at 0.2 mg/kg, po measured after 24 hrs by total ion chromatographic method	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
AID1487720	Cytotoxicity against HEK293 cells after 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	Targeting progesterone metabolism in breast cancer with l-proline derived new 14-azasteroids.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1803328	5α-R1 Activity Assay from Article 10.3109/14756366.2012.729827: \\In vivo and in vitro effect of androstene derivatives as 5a-reductase type 1 enzyme inhibitors.\\	2013	Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 28, Issue:6	In vivo and in vitro effect of androstene derivatives as 5α-reductase type 1 enzyme inhibitors.
AID1803329	5α-R2 Activity Assay from Article 10.3109/14756366.2012.729827: \\In vivo and in vitro effect of androstene derivatives as 5a-reductase type 1 enzyme inhibitors.\\	2013	Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 28, Issue:6	In vivo and in vitro effect of androstene derivatives as 5α-reductase type 1 enzyme inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346052	Human steroid 5 alpha-reductase 2 (1.-.-.- Oxidoreductases)	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (0.17)	18.7374
1990's	566 (24.18)	18.2507
2000's	818 (34.94)	29.6817
2010's	745 (31.82)	24.3611
2020's	208 (8.89)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	405 (16.11%)	5.53%
Reviews	455 (18.10%)	6.00%
Case Studies	99 (3.94%)	4.05%
Observational	5 (0.20%)	0.25%
Other	1,550 (61.65%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (67)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg and Merck & Co., Propecia Under Fasting Condition. [NCT01133444]	Phase 1	24 participants (Actual)	Interventional	2002-04-30	Completed
A Randomized, Single-dose, Two-treatment, Two-way, Crossover Bioequivalence Study of Finasteride 5 mg Tablets (Dr. Reddy's Laboratories Limited) With the Reference Formulation PROSCAR® 5 mg Tablet (Merck & Co., Inc.) Under Fed Conditions in Healthy Adult [NCT01264302]	Phase 1	26 participants (Actual)	Interventional	2006-11-30	Completed
Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database [NCT01381510]		54,459 participants (Actual)	Observational	2010-06-30	Completed
Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg and Merck & Co., Propecia in Healthy Adult Males Under Fed Condition. [NCT01133457]	Phase 1	24 participants (Actual)	Interventional	2002-04-30	Completed
High Risk Prostate Cancer Prevention Study [NCT01174953]		18 participants (Actual)	Interventional	2010-07-31	Completed
Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer [NCT02055170]	Phase 2	4 participants (Actual)	Interventional	2014-06-30	Terminated(stopped due to Unable to improve on poor accrual to study.)
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne [NCT02502669]	Phase 2	106 participants (Actual)	Interventional	2015-07-31	Completed
Phase 2 Multicenter Randomized Two Dose Level and Non-Inferiority Clinical Evaluation of Transrectal Administration of NX-1207 for the Treatment of BPH [NCT00759135]	Phase 2	85 participants (Actual)	Interventional	2007-05-31	Completed
A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness [NCT03004469]	Phase 3	458 participants (Actual)	Interventional	2016-08-02	Completed
A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Non-Fasting Conditions [NCT00835796]	Phase 1	20 participants (Actual)	Interventional	2002-06-30	Completed
A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fasting Conditions [NCT00835666]	Phase 1	32 participants (Actual)	Interventional	2002-06-30	Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Finasteride Tablets (5 mg; Mylan) and Proscar Tablets (5 mg; Merck) in Healthy Male Volunteers [NCT00648791]	Phase 1	29 participants (Actual)	Interventional	2004-09-30	Completed
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database [NCT01376258]		28,903 participants (Actual)	Observational	2010-10-31	Completed
A Randomized, Single-dose, Two-treatment, Two-way, Crossover Bioequivalence Study of Finasteride 5 mg Tablets (Dr. Reddy's Laboratories Limited) With the Reference Formulation PROSCAR® 5 mg Tablet (Merck & Co., Inc.) Under Fasting Conditions in Healthy Ad [NCT01264289]	Phase 1	26 participants (Actual)	Interventional	2006-11-30	Completed
Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test [NCT01296672]	Phase 4	383 participants (Actual)	Interventional	2011-02-28	Completed
H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis [NCT02548117]	Phase 3	0 participants (Actual)	Interventional	2016-02-29	Withdrawn(stopped due to Funding was not available.)
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males [NCT02781311]	Phase 2	169 participants (Actual)	Interventional	2016-07-14	Completed
A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance [NCT02146937]	Phase 2	0 participants (Actual)	Interventional	2014-03-31	Withdrawn(stopped due to Due to lack of accrual for this study. PI decided to close the study.)
A Randomized, Open-Label, Exploratory, Pharmacokinetic, Sequential Single Ascending Dose Study of IVL3001 Versus Propecia (Finasteride) Tablets in Healthy Adult Participants [NCT04945226]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2021-09-21	Completed
Imperial Prostate 4: Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer [NCT04049747]		2,450 participants (Anticipated)	Interventional	2019-12-11	Recruiting
Randomized, 2-Way Crossover Bioequivalence Study Finasteride 5 mg Tablet and Proscar Administrated as 1 x 5 mg Tablet in Healthy Subjects Under Fed Conditions [NCT00871247]	Phase 1	26 participants (Actual)	Interventional	2004-11-30	Completed
Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia [NCT05990400]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2023-05-01	Recruiting
The Efficacy of Topical Finasteride in the Treatment of Idiopathic Hirsutism [NCT00564252]		56 participants (Actual)	Interventional	2006-02-28	Completed
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy [NCT04288427]		120 participants (Anticipated)	Interventional	2020-09-25	Recruiting
Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study [NCT01391156]	Phase 3	40 participants (Actual)	Interventional	2011-03-31	Completed
MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia [NCT00127179]	Phase 3	600 participants (Actual)	Interventional	2004-01-01	Completed
A Randomized, Double Blind, Placebo Controlled Clinical Trial of L-SeMet Supplementation and Finasteride Treatment of Patients With Prostate Cancer Prior to Robotic Prostatectomy/Brachytherapy [NCT00736645]	Phase 2	55 participants (Actual)	Interventional	2008-08-31	Completed
A Feasibility Study of Oral Hormonal Therapy and Radiation for Non-metastatic, Intermediate or High Risk Prostate Cancer in Men 70 and Older or With Medical Comorbidities [NCT01342367]		74 participants (Actual)	Interventional	2010-12-17	Active, not recruiting
A Randomized Controlled Trial Evaluating the Tissue Effects of Preoperative Finasteride Versus Placebo for Patients With Clinically Organ-Confined Prostate Cancer [NCT00438464]	Phase 2	204 participants (Actual)	Interventional	2007-02-28	Completed
Study Evaluating the Association of CAG Repeat Polymorphisms and Finasteride Response in Women With Androgenetic Alopecia [NCT01052870]	Phase 1	12 participants (Actual)	Interventional	2008-12-31	Completed
On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP) [NCT00564460]	Phase 3	0 participants (Actual)	Interventional	2008-02-29	Withdrawn(stopped due to Change of practice pattern. Green light laser)
Randomized, 2-Way Crossover Bioequivalence Study Finasteride 5 mg Tablet and Proscar Administrated as 1 x 5 mg Tablet in Healthy Subjects Under Fasting Conditions. [NCT00870480]	Phase 1	26 participants (Actual)	Interventional	2004-11-30	Completed
Single-Dose Food In Vivo Bioequivalence Study of Finasteride Tablets (5 mg; Mylan) to Proscar® Tablets (5 mg; Merck) in Healthy Male Volunteers [NCT00650377]	Phase 1	30 participants (Actual)	Interventional	2004-10-31	Completed
A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia [NCT01231607]	Phase 3	917 participants (Actual)	Interventional	2010-10-28	Completed
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to B [NCT01139762]	Phase 3	696 participants (Actual)	Interventional	2010-09-30	Completed
A Within-subject, Randomized, Evaluator-blinded, Vehicle-controlled Study to Assess the Photosensitization Potential of Finasteride Cutaneous Solution(P-3074) in Human Subjects [NCT02791243]	Phase 1	58 participants (Actual)	Interventional	2016-05-09	Completed
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial of PROSCAR in Men With Initial Negative Prostate Biopsies [NCT00542243]	Phase 3	19 participants (Actual)	Interventional	2008-02-29	Completed
Pharmacokinetics of a Novel Oral Testosterone Undecanoate Formulation With Concomitant Inhibition of 5alpha-Reductase by Finasteride [NCT00842751]	Phase 2	11 participants (Actual)	Interventional	2009-07-31	Completed
Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia [NCT00064649]	Phase 3	49 participants (Actual)	Interventional	2004-04-30	Terminated(stopped due to Inability to recruit required sample size.)
Prostate Medication, Metabolism and Gut Microbiota [NCT06001619]	Phase 4	100 participants (Anticipated)	Interventional	2022-12-01	Recruiting
Pathophysiology-Guided Therapy for Sleep Apnea in the Elderly [NCT02703220]	Phase 4	100 participants (Anticipated)	Interventional	2015-07-03	Recruiting
Kinetics of the Finasteride Prostate Induced Apoptosis [NCT00130767]	Phase 4	90 participants	Interventional	2004-12-31	Active, not recruiting
Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy [NCT00837252]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2009-02-28	Completed
The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy [NCT00600691]	Phase 2	29 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Did not achieve enrollment goal and decided to terminate early)
Medical Therapy of Prostatic Symptoms [NCT00021814]	Phase 3	3,407 participants (Actual)	Interventional	1995-12-31	Completed
5-Alpha Reductase and Anabolic Effects of Testosterone [NCT00475501]	Phase 2	60 participants (Actual)	Interventional	2007-01-31	Completed
Oral Androgens in Man-6: Pharmacokinetics of Slow and Fast Release, External Matrix Oral Testosterone Formulations in Normal Men With Experimental Hypogonadism [NCT00663793]	Phase 1	16 participants (Actual)	Interventional	2008-10-31	Completed
A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) [NCT01643629]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2012-01-31	Active, not recruiting
Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia [NCT01334723]		35,032 participants (Actual)	Observational	2010-04-30	Completed
A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH [NCT01736033]	Phase 4	545 participants (Actual)	Interventional	2012-02-29	Active, not recruiting
Open Label, Randomized Comparative Study to Evaluate the Pharmacokinetic Characteristics Between Coadministered Finasteride Tablet and Tamsulosin HCl Tablet and GL2701 Capsule, in Healthy Subjects [NCT01829893]	Phase 1	26 participants (Actual)	Interventional	2012-01-31	Completed
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy [NCT01435954]		13,551 participants (Actual)	Observational	2010-08-31	Completed
Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy [NCT01227993]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2010-10-31	Completed
The Effect of Short Term Use of Finasteride Versus Cyproterone Acetate on Perioperative Blood Loss With Mono Polar Transurethral Resection of Prostate [NCT04848181]	Early Phase 1	60 participants (Actual)	Interventional	2019-07-01	Completed
A Phase II Study of Enzalutamide Plus Dutasteride/Finasteride as First Line Treatment for Vulnerable Patients ≥ 65 Years With Systemic Prostate Cancer [NCT02213107]	Phase 2	40 participants (Anticipated)	Interventional	2014-09-30	Active, not recruiting
MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, [NCT02244229]	Phase 4	403 participants (Actual)	Interventional	1998-04-30	Completed
An Open Label Study of 5α-reductase Inhibition on the Regulation of Insulin Action and Metabolic Phenotype in Healthy Volunteers. [NCT01923090]	Phase 2	12 participants (Anticipated)	Interventional	2012-08-31	Recruiting
A Phase III, Randomized Clinical Trial to Study the Safety and Efficacy of MK-906 (Finasteride) and Tamsulosin Administered Either Alone or Concomitantly in Patients With Benign Prostatic Hyperplasia (BPH) [NCT01534351]	Phase 3	1 participants (Actual)	Interventional	2013-08-01	Terminated(stopped due to Business Reasons)
The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia [NCT02483195]	Phase 4	0 participants (Actual)	Interventional	2016-08-31	Withdrawn(stopped due to PI indicating she was withdrawing her study submission due to lack of funding as of 6/20/2016)
A Phase-I, Open Label, Multi-Centre Clinical Study to Assess the Safety, Tolerability and Usability of FOL100 Lotion in Comparison to Oral Finasteride, for the Treatment of Androgenetic Alopecia [NCT05611593]	Phase 1	66 participants (Anticipated)	Interventional	2022-10-20	Recruiting
A Randomized, Active-Controlled, Double-Blind, Parallel Design, Multi-Center, Phase III Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) [NCT04032067]	Phase 3	423 participants (Actual)	Interventional	2019-10-30	Completed
National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopecia. [NCT04594018]	Phase 3	190 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI [NCT02248701]	Phase 2	33 participants (Actual)	Interventional	2017-04-27	Terminated(stopped due to Enrollment difficulties)
A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia [NCT00396175]	Phase 3	355 participants	Interventional	1998-03-31	Completed
A Phase II Trial of Potency-Sparing Hormonal Therapy in Patients With Elevated Serum PSA After Radiation Therapy or Radical Prostatectomy for Prostate Cancer [NCT00003323]	Phase 2	101 participants (Actual)	Interventional	1998-05-31	Completed
Phase II, Randomized, Placebo-Controlled Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy [NCT01585441]	Phase 2	6 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to This study was terminated early due to lack of enrollment.)
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment [NCT01386983]		332 participants (Actual)	Observational	2009-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00438464 (24) [back to overview]	Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Gleason Grade -- Specimen (Primary)
NCT00438464 (24) [back to overview]	Characteristics of Blood Biomarkers: Dihydrotestosterone (ng/dL) Percentage Change
NCT00438464 (24) [back to overview]	Characteristics of Blood Biomarkers: Estradiol (ng/dL) Percentage Change
NCT00438464 (24) [back to overview]	Characteristics of Blood Biomarkers: Estrone (ng/dL) Percentage Change
NCT00438464 (24) [back to overview]	Characteristics of Blood Biomarkers: Prostate-specific Antigen (ng/mL) Percentage Change (%)
NCT00438464 (24) [back to overview]	Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Zonal Origin of Tumor Foci Per Radical Prostatectomy Specimen (RPS)
NCT00438464 (24) [back to overview]	Comparison of Biomarkers Between Gleason Grades GG3 & GG4: Percentage of Tumor Cells Exhibiting Detectable Staining Within Finasteride Treatment Arm for Biomarker Subgroups
NCT00438464 (24) [back to overview]	Characteristics of Blood Biomarkers: Testosterone (ng/dL) Percentage Change
NCT00438464 (24) [back to overview]	Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Cancer Foci
NCT00438464 (24) [back to overview]	Comparison of Biomarkers Between Gleason Grades GG3 & GG4: Percentage of Tumor Cells Exhibiting Detectable Staining Within Placebo Treatment Arm for Biomarker Subgroups (Mean)
NCT00438464 (24) [back to overview]	Comparison of Biomarkers Between Gleason Grades GG3 & GG4: Percentage of Tumor Cells Within Placebo Treatment Arm for Biomarker Subgroups
NCT00438464 (24) [back to overview]	Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 3 (GG3) Biomarker Subgroups at Prostatectomy
NCT00438464 (24) [back to overview]	Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 3 (GG3) Biomarker Subgroups at Prostatectomy
NCT00438464 (24) [back to overview]	Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 4 (GG4) Biomarker Subgroup at Prostatectomy
NCT00438464 (24) [back to overview]	Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 4 (GG4) Biomarker Subgroup at Prostatectomy
NCT00438464 (24) [back to overview]	Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Gleason Grade -- Specimen (Secondary)
NCT00438464 (24) [back to overview]	Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Gleason Score
NCT00438464 (24) [back to overview]	Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Gleason Upgrade Between Biopsy and Prostatectomy
NCT00438464 (24) [back to overview]	Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Lymph Node Status
NCT00438464 (24) [back to overview]	Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Margin of Resection (MOR)
NCT00438464 (24) [back to overview]	Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Tumor Volume (Cubic Centimeter)
NCT00438464 (24) [back to overview]	Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Tumor, Node, Metastasis (TNM) Stage
NCT00438464 (24) [back to overview]	Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Zonal Origin -- Dominant Tumor Focus
NCT00438464 (24) [back to overview]	Comparison of Biomarkers Between Gleason Grades GG3 & GG4: Percentage of Tumor Cells Exhibiting Detectable Staining Within Finasteride Treatment Arm for Biomarker Subgroups (Mean)
NCT00475501 (11) [back to overview]	Dietary Protein Intake
NCT00475501 (11) [back to overview]	Life Satisfaction
NCT00475501 (11) [back to overview]	Hematocrit
NCT00475501 (11) [back to overview]	Grip Strength kg
NCT00475501 (11) [back to overview]	Geriatric Depression Scale
NCT00475501 (11) [back to overview]	Benton Judgment of Line Orientation Test
NCT00475501 (11) [back to overview]	30 Minute Recall Portion of Rey Osterrieth Complex Figure (ROCF) Test
NCT00475501 (11) [back to overview]	1 Repetition Maximum (1-RM) Strength Testing
NCT00475501 (11) [back to overview]	Lumbar Spine L2-L4 Bone Mineral Density
NCT00475501 (11) [back to overview]	Trail-Making Test, Part A
NCT00475501 (11) [back to overview]	Transrectal Ultrasound Sizing of Prostate
NCT00663793 (3) [back to overview]	Area Under the Curve-Serum T
NCT00663793 (3) [back to overview]	Area Under the Curve-E2
NCT00663793 (3) [back to overview]	Area Under the Curve-serum DHT
NCT00736645 (2) [back to overview]	Effects of Selenium and Finasteride and Their Combination on Apoptosis Induction
NCT00736645 (2) [back to overview]	Effects of Selenium and Finasteride and Their Combination on PSA Level
NCT00835666 (3) [back to overview]	AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00835666 (3) [back to overview]	AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00835666 (3) [back to overview]	Cmax - Maximum Observed Concentration
NCT00835796 (3) [back to overview]	AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00835796 (3) [back to overview]	AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00835796 (3) [back to overview]	Cmax - Maximum Observed Concentration
NCT00837252 (12) [back to overview]	Change in Serum Dihydrotestosterone (DHT) Concentration at Month 3 Compared to Baseline
NCT00837252 (12) [back to overview]	Change in Visual Acuity at Month 6 Compared to Baseline
NCT00837252 (12) [back to overview]	Change in Visual Acuity at Month 3 Compared to Baseline.
NCT00837252 (12) [back to overview]	Change in Urinary Cortisol Level at Month 6 Compared to Baseline
NCT00837252 (12) [back to overview]	Change in Center-Subfield Macular Thickness at Month 6 Compared to Baseline
NCT00837252 (12) [back to overview]	Change in Subretinal Fluid Volume at Month 6 Compared to Baseline
NCT00837252 (12) [back to overview]	Change in Center-Subfield Macular Thickness at Month 3 Compared to Baseline
NCT00837252 (12) [back to overview]	Change in Subretinal Fluid Volume at Month 3 Compared to Baseline
NCT00837252 (12) [back to overview]	Change in Serum Testosterone Level at Month 6 Compared to Baseline
NCT00837252 (12) [back to overview]	Change in Serum Testosterone Level at Month 3 Compared to Baseline
NCT00837252 (12) [back to overview]	Change in Serum Dihydrotestosterone (DHT) Concentration at Month 6 Compared to Baseline
NCT00837252 (12) [back to overview]	Change in Urinary Cortisol Level at Month 3 Compared to Baseline
NCT00842751 (3) [back to overview]	Maximum Testosterone Concentration
NCT00842751 (3) [back to overview]	Serum Estradiol Concentration
NCT00842751 (3) [back to overview]	Serum Dihydrotestosterone Concentration
NCT01139762 (14) [back to overview]	Change in International Index of Erectile Function (IIEF) - Intercourse Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks
NCT01139762 (14) [back to overview]	Change in International Index of Erectile Function (IIEF) - Overall Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks
NCT01139762 (14) [back to overview]	Change in International Index of Erectile Function (IIEF) - Sexual Desire Domain Scores From Baseline to 4, 12, and 26 Weeks
NCT01139762 (14) [back to overview]	Change in International Index of Erectile Function (IIEF) Question 3 and 4 Scores From Baseline to 4, 12, and 26 Weeks
NCT01139762 (14) [back to overview]	Change in International Prostate Symptom Score (IPSS) Quality of Life Index From Baseline to 4, 12, and 26 Weeks
NCT01139762 (14) [back to overview]	Change in International Prostate Symptom Score (IPSS) Subscores Index From Baseline to 4, 12, and 26 Weeks
NCT01139762 (14) [back to overview]	Change in Total International Prostate Symptom Score (IPSS) From Baseline to 4 and 26 Weeks
NCT01139762 (14) [back to overview]	Clinician Global Impression of Improvement (CGI-I) at 26 Weeks
NCT01139762 (14) [back to overview]	Patient Global Impression of Improvement (PGI-I) at 26 Weeks
NCT01139762 (14) [back to overview]	Change in International Index of Erectile Function (IIEF) - Orgasmic Function Domain Scores From Baseline to 4, 12, and 26 Weeks
NCT01139762 (14) [back to overview]	Change in Post Void Residual (PVR) Volume From Baseline to 26 Weeks
NCT01139762 (14) [back to overview]	Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks
NCT01139762 (14) [back to overview]	Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 26 Weeks
NCT01139762 (14) [back to overview]	Change in International Index of Erectile Function (IIEF) - Erectile Function Domain Scores From Baseline to 4, 12, and 26 Weeks
NCT01227993 (7) [back to overview]	Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at One Year Compared to Baseline
NCT01227993 (7) [back to overview]	Change in Serum Testosterone Levels at Two Years Compared to Baseline
NCT01227993 (7) [back to overview]	Change in Best-corrected Visual Acuity (BCVA) in the Fellow Eye at Two Years Compared to Baseline
NCT01227993 (7) [back to overview]	Change in Best-corrected Visual Acuity (BCVA) in the Fellow Eye at One Year Compared to Baseline
NCT01227993 (7) [back to overview]	Change in 24-hour Urine Cortisol Levels at Two Years Compared to Baseline
NCT01227993 (7) [back to overview]	Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at Two Years Compared to Baseline
NCT01227993 (7) [back to overview]	Change in Serum DHT Levels at Two Years Compared to Baseline
NCT01231607 (17) [back to overview]	Global Assessment of Improvement From Baseline to Week 24 Assessed for Vertex and Frontal Views Separately
NCT01231607 (17) [back to overview]	Change From Baseline in Investigator Photographic Assessment Questionnaire (IPAQ) Scores Assessed at Week 24 for Vertex and Frontal Views Separately
NCT01231607 (17) [back to overview]	Change From Baseline in Investigator Photographic Assessment Questionnaire (IPAQ) Scores Assessed at Week 12 for Vertex and Frontal Views Separately
NCT01231607 (17) [back to overview]	Change From Baseline in Hair Growth Index (HGI) Scores at Weeks 12 and 24
NCT01231607 (17) [back to overview]	Change From Baseline in Target Area Hair Count Within a 2.54 cm (1 Inch) Diameter Circle at the Vertex at Week 12 as Assessed by MT
NCT01231607 (17) [back to overview]	Change From Baseline in Target Area Hair Count Within a 1.13 cm (0.44 Inch) Diameter Circle at the Vertex, as Assessed by MT at Week 12
NCT01231607 (17) [back to overview]	Change From Baseline in Target Area Hair Count Within a 1.13 cm (0.44 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by MT
NCT01231607 (17) [back to overview]	Change From Baseline (BL) in Target Area Hair Count (HC) Within a 2.54 Centimeter (cm) (1 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by Macrophotographic Technique (MT)
NCT01231607 (17) [back to overview]	Change From Baseline in Total Hair Growth Satisfaction Scale (HGSS) Scores at Weeks 12 and 24
NCT01231607 (17) [back to overview]	Number of Participants With the Indicated Change From Baseline (BL) in the Stage (S) of Androgenic Alopecia (AGA) According to the Norwood-Hamilton Scale at Week 12 (W12)
NCT01231607 (17) [back to overview]	Change From Baseline in Target Area Hair Width Within a 2.54 cm (1 Inch) Diameter Circle at the Vertex at Week 12 and Week 24, as Assessed by MT
NCT01231607 (17) [back to overview]	Number of Participants With the Indicated Change From Baseline (BL) in the Stage (S) of Androgenic Alopecia (AGA) According to the Norwood-Hamilton Scale at Week 24
NCT01231607 (17) [back to overview]	Serum Concentration of Dutasteride at Week 12, Week 24, and Follow-up (Week 26)
NCT01231607 (17) [back to overview]	Serum Dihydrotestosterone (DHT) at Week 12, Week 24, and Follow-up (Week 26)
NCT01231607 (17) [back to overview]	Change From Baseline in Terminal Hair Count (THC) Within a 2.54 cm (1 Inch) Diameter Circle at the Vertex at Week 12 and Week 24, as Assessed by MT
NCT01231607 (17) [back to overview]	Change From Baseline in Terminal Hair Count Within a 1.13 cm (0.44 Inch) Diameter Circle at the Vertex at Week 12 and Week 24, as Assessed by MT
NCT01231607 (17) [back to overview]	Change From Baseline in Target Area Hair Width Within a 1.13 cm (0.44 Inch) Diameter Circle at the Vertex at Week 12 and Week 24, as Assessed by MT
NCT01296672 (3) [back to overview]	Pre/Post Ratio PSA Area Under the Curve (AUC)
NCT01296672 (3) [back to overview]	T2:ERG ( A Gene on Chromosome 21q22.2 That Encodes an Androgen-regulated Transmembrane Serine Protease Ratio to Estrogen Related Gene) Score AUC
NCT01296672 (3) [back to overview]	PCA3 (Prostate Cancer Antigen 3)Score AUC
NCT01334723 (8) [back to overview]	Mean BPH-Related Costs for Participants With an MPR >=70% Versus <70%
NCT01334723 (8) [back to overview]	Mean BPH-Related Costs for Participants With an MPR >=75% Versus <75%
NCT01334723 (8) [back to overview]	Mean BPH-Related Costs for Participants With an MPR >=80% Versus <80%
NCT01334723 (8) [back to overview]	Number of Participants With Risk of Acute Urinary Retention and Surgery Based on an MPR Threshold of 70%
NCT01334723 (8) [back to overview]	Number of Participants With Risk of Acute Urinary Retention and Surgery Based on an MPR Threshold of 75%
NCT01334723 (8) [back to overview]	Number of Participants With Risk of Acute Urinary Retention and Surgery Based on an MPR Threshold of 80%
NCT01334723 (8) [back to overview]	Mean Length of 5-ARI Therapy
NCT01334723 (8) [back to overview]	BPH-Related Costs for Every 30 Days of 5-ARI Therapy
NCT01342367 (2) [back to overview]	Percentage of Participants Free From Biochemical Failure
NCT01342367 (2) [back to overview]	Quality of Life Was Measured by the Expanded Prostate Cancer Index Composite (EPIC) Hormonal Health-related Quality of Life Questionnaire
NCT01386983 (2) [back to overview]	Number of Participants With Clinical Progression
NCT01386983 (2) [back to overview]	Dollar Amount of Enlarged Prostate (EP)-Related Medical Costs Incurred Per Month
NCT01534351 (2) [back to overview]	Number of Participants Who Experienced an Adverse Event
NCT01534351 (2) [back to overview]	Number of Participants Who Discontinued Treatment Due to an Adverse Event
NCT01585441 (23) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye at Month 3 Compared to Baseline
NCT01585441 (23) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye at the Safety Visit Compared to Baseline
NCT01585441 (23) [back to overview]	Number of Participants Presenting No Change in Autofluorescence Patterns at Month 3 Compared to Baseline
NCT01585441 (23) [back to overview]	Number of Participants Presenting No Change in Autofluorescence Patterns at the Safety Visit Compared to Baseline
NCT01585441 (23) [back to overview]	Changes in Best-corrected Visual Acuity (BCVA) in the Study Eye at the Safety Visit Compared to Baseline
NCT01585441 (23) [back to overview]	Number of Participants Presenting No Change in Fluid Leakage at Month 3 Compared to Baseline
NCT01585441 (23) [back to overview]	Number of Participants Presenting No Change in Fluid Leakage at the Safety Visit Compared to Baseline
NCT01585441 (23) [back to overview]	Number of Participants Presenting No Change in Size of Existing Plaque(s) on Indocyanine Green (ICG) Angiography at Month 3 Compared to Baseline
NCT01585441 (23) [back to overview]	Number of Participants Presenting No Change in Size of Existing Plaque(s) on Indocyanine Green (ICG) Angiography at the Safety Visit Compared to Baseline
NCT01585441 (23) [back to overview]	Number of Participants Who Withdrew From the Study
NCT01585441 (23) [back to overview]	Percent Change in Subretinal Fluid Volume in the Study Eye at Month 3 Compared to Baseline
NCT01585441 (23) [back to overview]	Proportion of Participants With a Reduction in Subretinal Fluid Volume ≥ 50% at 3 Months Compared to Baseline
NCT01585441 (23) [back to overview]	Proportion of Participants With an Improvement in Best-corrected Visual Acuity (BCVA) ≥ 15 Letters at 3 Months Compared to Baseline.
NCT01585441 (23) [back to overview]	Change in Serum Testosterone Concentration at the Safety Visit Compared to Baseline
NCT01585441 (23) [back to overview]	Change in Serum Testosterone Concentration at Month 3 Compared to Baseline
NCT01585441 (23) [back to overview]	Change in Central Retinal Thickness in the Study Eye at Month 3 Compared to Baseline
NCT01585441 (23) [back to overview]	Change in Central Retinal Thickness in the Study Eye at the Safety Visit Compared to Baseline
NCT01585441 (23) [back to overview]	Change in Serum Dihydrotestosterone (DHT) Concentration at Month 3 Compared to Baseline
NCT01585441 (23) [back to overview]	Change in Serum Dihydrotestosterone (DHT) Concentration at the Safety Visit Compared to Baseline
NCT01585441 (23) [back to overview]	Number of Participants With Adverse Reactions Related to the Investigational Product
NCT01585441 (23) [back to overview]	Change in Urinary Levels of Cortisol at Month 3 Compared to Baseline
NCT01585441 (23) [back to overview]	Change in Urinary Levels of Cortisol at the Safety Visit Compared to Baseline
NCT01585441 (23) [back to overview]	Changes in Best-corrected Visual Acuity (BCVA) in the Study Eye at Month 3 Compared to Baseline
NCT02248701 (6) [back to overview]	Absolute Change in Walking Speed
NCT02248701 (6) [back to overview]	Percent Change in Hip Bone Mineral Density
NCT02248701 (6) [back to overview]	Percent Change in Neuromuscular Function
NCT02248701 (6) [back to overview]	Percent Change in Total Body Fat
NCT02248701 (6) [back to overview]	Percent Change in Visceral Fat
NCT02248701 (6) [back to overview]	Percent Changes in Muscle Cross-Sectional Area
NCT02781311 (2) [back to overview]	Change From Baseline in Target Area Hair Count (TAHC) at Week 24
NCT02781311 (2) [back to overview]	Subject Self-Assessment (SSA) Score in Hair Growth at Week 24
NCT03004469 (9) [back to overview]	Adjusted Mean Change From Baseline in Target Area Hair Width (TAHW) in the Vertex at Weeks 12 and 24
NCT03004469 (9) [back to overview]	Adjusted Mean Change From Baseline in Participants Hair Growth/Loss at Weeks 12 and 24, Assessed for the Vertex by Blind Assessor
NCT03004469 (9) [back to overview]	Adjusted Mean Change From Baseline in Participants Hair Growth/Loss Assessed for the Vertex by Investigator at Weeks 12 and 24
NCT03004469 (9) [back to overview]	Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24
NCT03004469 (9) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
NCT03004469 (9) [back to overview]	Local Tolerability as Assessed by Incidence Rate of Skin Irritation Event Via Severity Score for Skin Irritation Scale
NCT03004469 (9) [back to overview]	Adjusted Mean Change From Baseline in Hair Growth Assessed by TAHC in the Vertex at Week 12
NCT03004469 (9) [back to overview]	Adjusted Mean International Index of Erectile Function (IIEF-2) Scores at Weeks 4, 8, 12 and 24
NCT03004469 (9) [back to overview]	Adjusted Mean Overall Male Hair Growth Questionnaire (MHGQ) Score as Assessed by the Participant at Weeks 12 and 24

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Gleason Grade -- Specimen (Primary)

Frequency of Grade 3 and Grade 4 tumors in two treatment groups: Participants consist of men with adenocarcinoma of the prostate, clinical stage T1c or T2, with a Gleason score of 6 or 7 and a PSA level < 10 ng/mL, who are scheduled to undergo prostatectomy. (NCT00438464)
Timeframe: Assessment following maximum 6 week treatment period and prostatectomy

Intervention	participants (Number)
	Grade 3	Grade 4
Arm I (Finasteride)	65	23
Arm II (Placebo)	75	18

Intervention	participants (Number)
	PZ	PZ + TZ	PZ + TZ + CZ	PZ + CZ	TZ
Arm I (Finasteride)	35	49	2	0	3
Arm II (Placebo)	38	50	2	1	3

Intervention	Percentage of tumor cell involvement (Median)
	VEGF (N=37,48)	ERβ (N=35,48)	AR (N=35,48)	Ki-67 (N=37,48)	SRD5A2 (N=45,38)	UBE2C (N=34,46)	Caspase (N=38,47)
Within GG3, Finasteride Arm	80	15.0	75.2	1.1	100	0.4	0.2
Within GG4, Finasteride Arm	85	8.0	63.7	1.3	95	0.3	0.06

Intervention	participants (Number)
	1 Focus	2 Foci	3 Foci	4 Foci	>/= 5 Foci
Arm I (Finasteride)	15	18	28	13	15
Arm II (Placebo)	11	20	28	20	15

Intervention	Percentage of tumor cell involvement (Mean)
	VEGF (N=55,61)	ERβ (N=55,62)	AR (N=54,62)	Ki-67 (N=54,62)	SRD5A2 (N=47,69)	UBE2C (N=55,62)	Caspase (N=55,61)
GG3, Within Placebo Arm	63.7	14.8	72.4	1.5	64.7	0.5	0.2
GG4, Within Placebo Arm	59.7	16.7	68.6	1.7	64.9	0.5	0.06

Intervention	Percentage tumor cell involvement (Median)
	VEGF (N=37,55)	ERβ (N=35, 55)	AR (N=35, 54)	Ki-67 (N=37,54)	SRD5A2 (N=45,47)	UBE2C (N=34,55)	Caspase (N=38,55)
Finasteride Arm Within GG3	80	15.0	75.2	1.1	100	0.4	0.2
Placebo Arm Within GG3	90	6.6	78.3	1.3	90	0.3	0.08

Intervention	Percentage of tumor cell involvement (Median)
	VEGF (N=48,61)	ERβ (N=48,62)	AR (N=48,62)	Ki-67 (N=48,62)	SRD5A2 (N=38,69)	UBE2C (N=46,62)	Caspase (N=47,61)
Finasteride Arm Within GG4	85	8.0	63.71	1.3	95	0.3	0.06
Placebo Arm Within GG4	70	9.5	75.9	1.4	90	0.3	0.04

Intervention	participants (Number)
	Grade 3	Grade 4	Grade 5
Arm I (Finasteride)	31	53	4
Arm II (Placebo)	24	64	5

Intervention	participants (Number)
	Gleason Score 6	Gleason Score 7	Gleason Score 8	Gleason Score 9
Arm I (Finasteride)	12	71	2	3
Arm II (Placebo)	10	78	1	4

Intervention	participants (Number)
	Positive	Negative	Equivocal
Arm I (Finasteride)	17	67	5
Arm II (Placebo)	16	76	2

Intervention	cubic centimeter (Median)
	Total	PZ Cancer focus/foci	TZ cancer focus/foci
Arm I (Finasteride)	1.0	0.6	0.0
Arm II (Placebo)	0.8	0.5	0.0

Intervention	gm/body weight (kg) (Mean)
	protein intake baseline	protein intake 3 months	protein intake 6 months	protein intake 9 months	protein intake 12 months n = 1,1,2,5
Arm 1	0.97	0.87	0.74	1.15	1.18
Arm 2	1.06	0.94	1.27	1.20	0.74
Arm 3	0.99	1.49	1.05	1.26	1.39
Arm 4	1.00	1.12	0.93	0.82	1.05

Intervention	points (Mean)
	Life Satisfaction A baseline	Life Satisfaction A 3 months	Life Satisfaction A 6 months	Life Satisfaction A 9 months	Life Satisfaction A 12 months
Arm 1	13.83	12.67	13.70	14.75	15.17
Arm 2	12.08	12.11	14.44	13.44	12.5
Arm 3	11.35	12.27	11.20	11.57	12.17
Arm 4	12.69	14.13	13.54	13.17	13.83

Intervention	% volume (Mean)
	hematocrit baseline %	change hematocrit 3 months %	change hematocrit 6 months %	change hematocrit 9 months %	change hematocrit 12 months %
Arm 1	42.6	3.6	4.044	4.071	5.22
Arm 2	41.2	0.611	0.557	0.63	-1.175
Arm 3	42.0	4.593	4.331	3.38	4.173
Arm 4	40.3	-0.06	0.514	-0.155	-0.192

Intervention	kg (Mean)
	grip strength baseline kg	change grip strength 3 month kg	change grip strength 6 month kg	change grip strength 9 month kg	change grip strength 12 month kg
Testosterone Finasteride	18.2	0.485	1.00	1.331	1.174
Testosterone Vehicle	17.0	1.66	2.02	1.558	1.909
Vehicle Finasteride	16.9	-0.045	0.812	1.25	1.477
Vehicle Placebo	17.472	0.212	-0.035	0.152	0.72

Intervention	units on a scale (Mean)
	depression baseline	depression 3 months	depression 6 months	depression 9 months	depression 12 months
Testosterone Finasteride	4.93	3.23	5.0	3.69	3.73
Testosterone Vehicle	2.38	1.80	1.5	0.88	3.33
Vehicle Finasteride	3.08	2.90	2.22	1.89	2.88
Vehicle Placebo	2.13	1.67	1.62	2.92	1.83

Intervention	units on a scale (Mean)
	Benton baseline	Benton 3 months	Benton 6 months	Benton 9 months	Benton 12 months
Arm 1	24.54	25.00	25.90	25.38	25.67
Arm 2	24.39	25.40	25.11	23.89	25.5
Arm 3	25.88	25.07	26.0	25.79	26.17
Arm 4	24.69	25.67	25.08	24.92	24.08

Intervention	units on a scale (Mean)
	Rey baseline	Rey 3 month	Rey 6 month	Rey 9 month	Rey 12 month
Arm 1	12.42	16.68	15.76	15.25	16.86
Arm 2	13.54	12.85	16.17	15.17	15
Arm 3	12.82	16.27	17.38	18.08	19.27
Arm 4	12.8	12.5	14	15.55	16.45

Intervention	kg (Mean)
	leg press baseline Kg	leg press 3-months change kg	leg press 6-months change kg	leg press 9-months change kg	leg press 12-months change kg
Arm 1	129.1	9.192	10.227	14.416	14.773
Arm 2	109.4	-1.34	-1.136	-5.55	0
Arm 3	137.2	9.679	13.778	10.49	12.5
Arm 4	118.8	-2.44	2.727	2.02	1.515

Intervention	gm/cc (Mean)
	L2-L4 spine BMD baseline gm/cc	change L2-L4 spine BMD 12 month gm/cc
Arm 1	1.03	0.049
Arm 2	1.02	0.002
Arm 3	0.99	0.053
Arm 4	1.07	-0.020

Intervention	sec (Mean)
	Trails A baseline	Trails A 3 months	Trails A 6 months	Trails A 9 months	Trails A 12 months
Arm 1	37.59	38.5	32.9	31.0	29.17
Arm 2	46.42	42.1	39.0	38.56	40.0
Arm 3	36.65	33.53	31.2	29.07	32.5
Arm 4	44.0	44.33	36.92	43.17	43.75

finasteride

Description

Cross-References

Synonyms (162)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (3)

Protein Targets (41)

Potency Measurements

Inhibition Measurements

Biological Processes (147)

Molecular Functions (68)

Ceullar Components (41)

Bioassays (424)

Research

Studies (2,341)

Study Types

Clinical Trials (67)

Trial Overview

Trial Outcomes

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Gleason Grade -- Specimen (Primary)

Characteristics of Blood Biomarkers: Dihydrotestosterone (ng/dL) Percentage Change

Characteristics of Blood Biomarkers: Estradiol (ng/dL) Percentage Change

Characteristics of Blood Biomarkers: Estrone (ng/dL) Percentage Change

Characteristics of Blood Biomarkers: Prostate-specific Antigen (ng/mL) Percentage Change (%)

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Zonal Origin of Tumor Foci Per Radical Prostatectomy Specimen (RPS)

Comparison of Biomarkers Between Gleason Grades GG3 & GG4: Percentage of Tumor Cells Exhibiting Detectable Staining Within Finasteride Treatment Arm for Biomarker Subgroups

Characteristics of Blood Biomarkers: Testosterone (ng/dL) Percentage Change

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Cancer Foci

Comparison of Biomarkers Between Gleason Grades GG3 & GG4: Percentage of Tumor Cells Exhibiting Detectable Staining Within Placebo Treatment Arm for Biomarker Subgroups (Mean)

Comparison of Biomarkers Between Gleason Grades GG3 & GG4: Percentage of Tumor Cells Within Placebo Treatment Arm for Biomarker Subgroups

Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 3 (GG3) Biomarker Subgroups at Prostatectomy

Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 3 (GG3) Biomarker Subgroups at Prostatectomy

Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 4 (GG4) Biomarker Subgroup at Prostatectomy

Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 4 (GG4) Biomarker Subgroup at Prostatectomy

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Gleason Grade -- Specimen (Secondary)

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Gleason Score

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Gleason Upgrade Between Biopsy and Prostatectomy

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Lymph Node Status

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Margin of Resection (MOR)

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Tumor Volume (Cubic Centimeter)

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Tumor, Node, Metastasis (TNM) Stage

Pathologic Characteristics of Radical Prostatectomy Specimens After Treatment: Zonal Origin -- Dominant Tumor Focus

Comparison of Biomarkers Between Gleason Grades GG3 & GG4: Percentage of Tumor Cells Exhibiting Detectable Staining Within Finasteride Treatment Arm for Biomarker Subgroups (Mean)

Dietary Protein Intake

Life Satisfaction

Hematocrit

Grip Strength kg

Geriatric Depression Scale

Benton Judgment of Line Orientation Test

30 Minute Recall Portion of Rey Osterrieth Complex Figure (ROCF) Test

1 Repetition Maximum (1-RM) Strength Testing

Lumbar Spine L2-L4 Bone Mineral Density

Trail-Making Test, Part A

Transrectal Ultrasound Sizing of Prostate

Area Under the Curve-Serum T

Area Under the Curve-E2

Area Under the Curve-serum DHT

Effects of Selenium and Finasteride and Their Combination on Apoptosis Induction

Effects of Selenium and Finasteride and Their Combination on PSA Level

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Cmax - Maximum Observed Concentration

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Cmax - Maximum Observed Concentration

Change in Serum Dihydrotestosterone (DHT) Concentration at Month 3 Compared to Baseline

Change in Visual Acuity at Month 6 Compared to Baseline

Change in Visual Acuity at Month 3 Compared to Baseline.

Change in Urinary Cortisol Level at Month 6 Compared to Baseline

Change in Center-Subfield Macular Thickness at Month 6 Compared to Baseline

Change in Subretinal Fluid Volume at Month 6 Compared to Baseline

Change in Center-Subfield Macular Thickness at Month 3 Compared to Baseline

Change in Subretinal Fluid Volume at Month 3 Compared to Baseline

Change in Serum Testosterone Level at Month 6 Compared to Baseline

Intervention	cc (Mean)
	postate volume baseline cc	change prostate volume 6 months cc	change prostate volume 12 months cc
Arm 1	26.4	7.626	11.42
Arm 2	29.7	-1.984	-4.93
Arm 3	37.1	-3.927	-1.72
Arm 4	36.9	-1.474	-2.891

Intervention	nmol*h/L (Mean)
	external matrix 'immediate' release	external matrix 'fast' release	external matrix 'slow' release
Testosterone Only	143	144	162
Testosterone Plus Finasteride	198	384	237

Intervention	percentage of apoptotic cells (Median)
Arm A: Finasteride + Selenium Placebo	0.1
Arm B: Finasteride + Selenium	0
Arm C: Finasteride Placebo + Selenium Placebo	0
Arm D: Finasteride Placebo + Selenium	0

Intervention	ng*hr/dL (Geometric Mean)
Acyline +Testosterone Undecanoate + Placebo	471
Acyline +Testosterone Undecanoate + 0.5mg Finasteride	444
Acyline +Testosterone Undecanoate + 1mg Finasteride	543

Intervention	ng*hr/dL (Geometric Mean)
Acyline +Testosterone Undecanoate + Placebo	7.9
Acyline + Testosterone Undecanoate + 0.5mg Finasteride	6.5
Acyline +Testosterone Undecanoate + 1mg Finasteride	7.2

Intervention	ng*hr/dL (Geometric Mean)
Acyline +Testosterone Undecanoate + Placebo	154
Acyline + Testosterone Undecanoate + 0.5mg Finasteride	118
Acyline + Testosterone Undecanoate + 1mg Finasteride	125

Intervention	units on a scale (Least Squares Mean)
	4 weeks	12 weeks	26 weeks
Placebo	-0.46	0.08	-0.26
Tadalafil	1.36	1.68	1.72

Intervention	units on a scale (Least Squares Mean)
	Question 3 - 4 weeks	Question 3 - 12 weeks	Question 3 - 26 weeks	Question 4 - 4 weeks	Question 4 - 12 weeks	Question 4 - 26 weeks
Placebo	-0.32	0.04	-0.07	-0.21	0.13	0.06
Tadalafil	0.42	0.72	0.68	0.49	0.74	0.68

Intervention	units on a scale (Least Squares Mean)
	IPSS storage (irritative) subscore - 4 weeks	IPSS storage (irritative) subscore - 12 weeks	IPSS storage (irritative) subscore - 26 weeks	IPSS voiding (obstructive) subscore - 4 weeks	IPSS voiding (obstructive) subscore - 12 weeks	IPSS voiding (obstructive) subscore - 26 weeks
Placebo	-0.76	-1.34	-1.66	-1.47	-2.37	-2.77
Tadalafil	-1.27	-1.74	-2.00	-2.65	-3.41	-3.50

Intervention	participants (Number)
	1 = Very much improved	2 = Much improved	3 = Minimally improved	4 = No change	5 = Minimally worse	6 = Much worse	7 = Very much worse
Placebo	22	97	106	48	10	6	1
Tadalafil	23	129	98	47	5	5	0